
















The Dissertation Committee for Matthew Wayne Lluis Certifies that this is the 
approved version of the following dissertation: 
 
 
Crystal Structures of Dimethylarginine Dimethylaminohydrolase-1 
(DDAH-1) from Homo Sapiens Bound to the Inhibitors N5-(1-
iminopentyl)-L-ornithine and Ebselen  
and 








Jon D. Robertus, Supervisor 
Kenneth A. Johnson 
George Georgiou 
Scott W. Stevens 
Walter L. Fast 
 Crystal Structures of Dimethylarginine Dimethylaminohydrolase-1 
(DDAH-1) from Homo Sapiens Bound to the Inhibitors N5-(1-
iminopentyl)-L-ornithine and Ebselen  
and 










Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Doctor of Philosophy 
 
 

















Thanks to the Robertus Lab: Dr. Robertus for the great degrees of freedom and 
patience in the workplace (it’s too bad those conversations on cosmic inflation, dark 
matter, and the spacetime continuum were not more frequent), Dr. Arthur F. Monzingo 
for the great degrees of help with data collection, processing, and especially crystal 
looping, Huda S. (“The Sudaner”) Suliman (not Suleman), Warren X. Hoe (The man of 
Troy), and Joshua C. Russel for their help, encouragement, friendship, and participation 
in conversations on the USC two-deep, religion, middle eastern culture, drop D tuning, 
retro air jordans, and life as we know (and will know) it, along with other assorted and 
not so related topics, Yan Bai and Shuangluo Xia, and the most recent additions: 
Devinder Ubhi, Karl Jasheway, and Beth Watt.  I would also like to thank graduate 
students from other labs for their help: Clint Leysath, Venu Bhaskara, Simrit Dhaliwal, 
and Michael Dennis, and my friends outside of UT Campus and Austin: Anelis (‘Lis) M. 
Vazquez (Mi otro hermana…por vida) for her genuine friendship, Jesell Lopez for 
genuinely being herself (don’t ever change, girl…we’ll meet again), Christopher 
Caravello and Sal Scardino for being authentic, my other B.R.O.E.S., Michael Hunter (I 
don’t think we are ever going to top 9th grade geometry class), BP for Repo Man, Joe 
from Lord’s Boxing Gym, my S.D.M.F.s worldwide, Casey Sanders for the early days 
(I’ll never forget ’93, brother), Luis Pinzon and Ling Feng Schuchert for the latter days 
 vi
(I’m never going to forget ’02 and ’03 either), and Johnny Chang for all the days in 
between (’95 and ’96, those were some good days, guy…those were definitely some 
good days) and those days still to come…no matter how far off they may be, Sneauxball 
for bringing me down to the Irish Channel (“How you doin’, sweetheart!”), Alex at 
LBTR in NOLA (“Can I get another water?”), Justyna and Diana in Barcelona, the girl 
on that train in Lisbon for sending me a message (Eu ainda não entendi isto…mas eu sei 
que significou algo), Hannah “Barbera” from BD’s, Leroy Kevin Webb (my all-time 
favorite teammate), Clive Francis, Paul Werner (best class ever), Mr. Saltzgaver, Mrs. 
Stewart, Coach Billy Turner, Jason C. for that day at the greenbelt (like GW crossing the 
Delaware), Joe and Marco for that one at Hamilton Pool, Jeff Baker for turning the corner 
(’99 was a weird time, kid), Pablo R., A.J. Hoffman, Kevin Willis and Charles Oakley, 
Anthony Poindexter, Arthur Dabney (especially), the two best blood relatives I have: 
Victor Hugo Lluis and Cousin Kris (with a “K”) for their wisdom, limitless knowledge, 
and intricate personalities, my extended family: Aunt Aida, Aunt Sonja, Aunt Tita, 
Cousin Et, and Ellen Leahy amongst many others, Mike Reeder and Marc Heard from 
HPG for their encouragement, Dr. Edward Turos and Dr. Jesse Binford, and the Kings of 
Metal for being born for a reason and living legendary (cause they’re going to be ageless, 
timeless, ageless and timeless…for fkn’ ever).  Finally, I would like to send my deepest 
thanks to the two people I owe the most to, my Mother and Father.  From them I inherited 
a good last name and the reputation that goes with it.  I hope that when this life is 
over…it can be said that I made my own contribution to that.       
    
 vii
Crystal Structures of Dimethylarginine Dimethylaminohydrolase-1 
(DDAH-1) from Homo Sapiens Bound to the Inhibitors N5-(1-
iminopentyl)-L-ornithine and Ebselen  
and 





Matthew Wayne Lluis, Ph.D. 
The University of Texas at Austin, 2009 
 
Supervisor:  Jon D. Robertus 
 
Nitric oxide (NO) is reactive, radical gas that is involved in a myriad of cellular 
signaling pathways including the regulation of blood flow and immunodefense.  NO is 
produced from the oxidation of L-arginine to L-citrulline by nitric oxide synthase (NOS).  
The activity of NOS and by default, the production of NO, is regulated by the arginine 
derivatives Nω,Nω-dimethyl-L-arginine (ADMA) and Nω-monomethyl-L-arginine 
(NMMA) which arise from the proteolytic degradation of post translationally methylated 
proteins.  The cellular concentrations of ADMA and NMMA are regulated by the enzyme 
dimethylarginine dimethylaminohydrolase (DDAH), which catabolizes these compounds 
to L-citrulline and dimethylamine or methyl amine, respectively.  Because over and under 
production of NO has been implicated in several pathophysiological states, compounds 
that control NO production by inhibiting NOS or DDAH may prove useful as treatments.  
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In this study, the crystal structures of human DDAH-1 with the inhibitors N5-(1-
iminopentyl)-L-ornithine (L-IPnO) and ebselen were solved to 2.9 and 2.0 Å resolution, 
respectively.  L-IPnO was observed to inhibit DDAH-1 in essentially the same manner as 
another amidino-containing inhibitor: docking to the enzyme via hydrogen bond and ion 
pair interactions and forming a covalent adduct with the active site cysteine.  Ebselen was 
also observed to covalently attach to the active site cysteine, however, the docking 
mechanism was absent of hydrogen bond and ion pair interactions.  The work presented 
here contributes to the design of compounds that may effectively regulate the production 
of NO for therapeutic purposes. 
Translin is a highly conserved mammalian RNA and DNA binding protein known 
to be involved in DNA recombination and repair, RNA trafficking in neurons, and post-
transcriptional regulation of gene expression in male germ cells.  Although crystal 
structures of the mouse and human orthologs of translin have been solved, they do not 
provide details on the structure-function relationship of the protein.  Studies have 
identified a partner protein for translin, translin associated factor x (trax), which is 
believed to have a crucial role in assisting translin with its cellular functions.  It is 
believed that trax regulates translin’s affinity for certain RNA and DNA sequences.  In 
this work the binding affinities of translin and the translin●trax complex were 
investigated.  It was observed that translin preferentially binds to G-rich RNA sequences, 
most likely recognizing a secondary structure intrinsic to these sequences, whereas 
translin●trax preferentially binds G-rich DNA sequences.  The results from these 
experiments provide insight into the cellular functions of translin and trax and their 
respective roles in mRNA trafficking.        
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Chapter 1:  Introduction 
 
Nitric Oxide  
Nitric oxide (NO) is a reactive, radical gas used by vertebrates for cellular 
processes including neurotransmission, immunodefense, and regulating blood vessel 
dilation [1, 2].  NO is a highly labile compound that can diffuse freely across the cellular 
membrane, making it an ideal transient signaling molecule [1, 3].  NO is synthesized by 
the oxidation of arginine’s guanidino nitrogen by the enzyme nitric oxide synthase 
(NOS), which uses NADPH and O2 to produce NO and L-citrulline in a 1:1 ratio 
(Figure1.1) [1].   
In mammals, nitric oxide is produced by three nitric oxide synthase isozymes: 
neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS) [4, 5].  
nNOS produces NO in the nervous tissue for cellular signaling between neurons [4, 5].  
Phagocytes are equipped with iNOS for the purpose of NO production as an immune 
response [4, 5].  eNOS produces NO in the vascular system in order to control blood flow 
[4, 5].  Considering the fact that it is a signaling molecule for cellular processes as 
disparate as mediation of blood flow and immunodefense, it comes as no surprise that the 
biochemistry of NO is versatile and complex [1, 2, 5].  NO exists as a free radical and 
nitrogen can exist in several oxidation states including +1 in the nitroxyl ion NO-, +2 in 
the nitric oxide free radical NO. and the nitrosium ion NO+, +3 in the nitrite ion NO2-, and 
+5 in the nitrate ion NO3- [5].  These chemical properties grant NO the ability to react 
 2
with metals, thiols, and oxides, allowing it to activate or inhibit proteins directly or 




Figure 1.1: Synthesis of NO.  Nitric oxide synthase catalyzes the oxidation of L-arginine 
to produce L-citrulline and NO [3]. 







As an example, guanylyl cyclase is a physiological target that is activated 
indirectly by NO.  NO binding to the Fe+2 of the heme group of the enzyme induces a 
conformational change that activates the enzyme leading to an increase in the cellular 
concentration of cyclic GMP [5].  Alternatively, NO has also been shown to react with 
the Fe-S cluster of aconitase, leading to the inhibition of that enzyme [5].  Because NO 
reactivity is so versatile and is at least in some way tied to the redox state of the cell, NO 
levels can affect many signaling pathways (Figure 1.2) and as a result can have both 
protective and detrimental effects [5].   
Interestingly, under- and overproduction of NO has been linked to various 
diseases and disorders, with overproduction causing conditions such as septic shock and 
rheumatoid arthritis, and low NO levels being associated with hypertension and renal 
failure among other pathogenic states [3, 5, 6].  Additionally, previous studies have 
shown varying levels of NO production to produce contradictory results, such as 
inhibiting cancer growth at high cellular levels but facilitating cancer growth at levels 10-
100-fold lower, both inducing and preventing apoptosis, and add to or defend against 
damage after stroke [7-14].  Due to it’s dichotomous biochemistry, NO has been 
figuratively described in the literature as a “double-edged sword”.  Because of its direct 
or indirect involvement in the diseases and disorders previously mentioned and the 
complexity of controlling its production, regulation of NO production is a very active 
research field.   




Figure 1.2: The effects of NO at high and low cellular concentration.  At high 
concentrations (greater than 1μM), NO can nitrosylate the γS of active site cysteines of 
enzymes like thioredoxin (Thiordxn) and dimethylarginine dimethylaminohydrolase 
(DDAH), which can result in both activation (thioredoxin) and inhibition (DDAH) of 
these enzymes.  High concentrations of NO also leads to the deamination of cytosine to 
thymidine, and nitration of tyrosine residues in enzymes like ribonucleotide reductase 
(RiboNRed, resulting in inhibition) and prostaglandin H synthase (ProstHSyn, resulting 
in activation).  At low concentrations (less than 1μM) NO can react with Fe containing 
heme groups of enzymes that can result in inhibition (aconitase) or activation (guanylyl 





Nitric Oxide Synthases 
 
To reiterate, in mammals, three isozymes of Nitric Oxide Synthase exist: nNOS, 
iNOS, and eNOS.  These isoforms share 51-57% homology between them and all three 
exist as homodimeric proteins with each subunit 125 – 160 kDa in size and consisting of 
two domains [4].  The ~500 residue N-terminal oxygenase domain contains the dimer 
interface and catalyzes the 5 electron oxidation of L-arginine to produce NO and L-
citrulline [4].  The ~600 residue C-terminal reductase domain provides the electrons for 
the reaction [4].  Since NO is so widely used for inducing physiological responses in 
wide ranging tissues, regulation of NOS activity is complex.  For the eNOS and nNOS 
isoforms the primary mode of regulation is activation by Ca+2-calmodulin binding to a 
region encompassing the first 30 amino acids of the protein’s C-terminal domain [4].  
Alternatively, iNOS is not activated by Ca+2-calmodulin and it is primarily activated by 
transcriptional induction [4].  Additionally, it is also known that the activities of the three 
mammalian NOS isoforms are regulated in some way by phosphorylation and other 
protein-protein interactions [4].   
However, a key part of NOS regulation, and by default regulation of the 
production of NO involves endogenous methyl arginine derivatives.  Specifically, 
asymmetric Nω,Nω-dimethyl-L-arginine (ADMA) and Nω-monomethyl-L-arginine 
(NMMA) have proven to be endogenous inhibitors of all three isoforms of NOSs in 
mammals [15] (Figure 1.3).  Methylarginines originate from the proteolytic degradation 
of proteins whose arginine residues were post-translationally methylated by protein 
arginine methyl transferases (PRMTs) [15].  Recent research has flagged ADMA as a 
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biomarker of cardiovascular disease.  High ADMA levels have been linked to serious 
cardiovascular conditions including hypercholesterolemia, atherosclerosis, high-blood 
pressure, and chronic heart failure [16, 17].  Additionally, elevated ADMA levels have 
also been linked to chronic renal failure and diabetes mellitus [18].  In a healthy 
individual, about 10% of the ADMA pool is eliminated by excretion via the kidneys [19].   
The balance of the ADMA pool is eliminated via a catabolic pathway in which the 
enzyme dimethylarginine dimethylaminohydrolase (DDAH) degrades ADMA into L-
citrulline and dimethyl amine [15, 20, 21] (Figure 1.4 and Figure 1.5).  DDAH also 
regulates the pool of NMMA in the plasma, breaking this methyl arginine down into L-




Figure 1.3: The structures of asymmetric Nω,Nω-dimethyl-L-arginine (ADMA) and Nω-
monomethyl-L-arginine (NMMA).  These methyl arginine derivates are endogenous 
inhibitors of all three mammalian isoforms of NOS and originate from the proteolytic 
degradation of proteins which contain methylated arginine residues. 









Figure 1.4: Hydrolysis of ADMA and NMMA.  DDAH converts ADMA or NMMA to 
L-citrulline and dimethyl amine or methyl amine, respectively.  DDAH catalyzes this 
conversion without any known cofactors.  In a healthy individual, only 10% of the 
ADMA pool is eliminated by renal excretion, the remainder is removed by the DDAH 
pathway [19]. 







Figure 1.5: The roles of DDAH, ADMA, and NMMA in the regulation of NO 
production.  Nitric oxide synthase (NOS) catalyzes the oxidation of L-arginine to yield 
nitric oxide (NO) and L-citrulline.  The methyl arginine derivatives ADMA and NMMA, 
which originate from the proteolytic breakdown of methylated proteins, are endogenous 
inhibitors of NOS.  Dimethylarginine dimethylaminohydrolase (DDAH) catabolizes 
ADMA and NMMA, and is itself inhibited by NO in a feedback mechanism.  This figure 








DDAH Structures and Mechanism 
 
As described above, NO levels are partly regulated by asymmetric 
methylarginines, and asymmetric methylarginines are catabolized by DDAH. Mammals 
use two isoforms of dimethylarginine dimethylaminohydrolase (DDAH), DDAH-1 and 
DDAH-2, to regulate the plasma levels of ADMA and NMMA [22, 23].  DDAH-1 is the 
predominant DDAH isozyme in neuronal tissues where nNOS is enriched, whereas 
DDAH-2 predominates in the endothelial tissues where it is co-expressed with eNOS [22, 
23].  DDAH hydrolyzes ADMA or NMMA to L-citrulline and dimethylamine or 
methylamine, respectively, without any known cofactors.  Interestingly, mammalian 
DDAH-1 and DDAH-2, by sequence similarity, are not homologous to other mammalian 
enzymes involved in arginine metabolism.  Furthermore, DDAH enzymes have been 
identified in certain microbes as components of conserved arginine catabolizing operons, 
an unexpected observation considering that these microbes do not produce methylated 
arginine derivatives [24, 25].   
Murray-Rust et al solved the first DDAH structure from the bacterium 
Pseudomonas aeruginosa (Pa).  The 2.37Å structure of the apoenzyme crystallized as a 
dimer.  The overall topology of the Pa DDAH monomer is that of a barrel built from five 
ββαβ repeats with the active site lying in a negatively charged pocket at the center of the 
barrel (Figure 1.6) [26].  Additional structures of Pa DDAH complexed with both 
ADMA and L-citrulline gave detailed insight into the dynamics and interactions involved 
in substrate docking.   
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It was observed that residues 14-25, which are disordered in the unliganded 
DDAH structure, form a flexible loop that closes over the active site channel when 
substrate is bound [26] (Figure 1.7).  This ‘cover’ is ‘latched’ by a direct hydrogen bond 
contact between the main chain carbonyl of Leu18 and the α-amino group of the 
substrate.  At the active site, DDAH employs a system of hydrogen bonds to immobilize 





Figure 1.6: Structure of Pa DDAH.  A cartoon structure figure of Pa DDAH showing the 
propeller formed by the five ββαβ repeats of the enzyme.  This view is looking into the 
active site pocket.  α-helices are shown as red cylinders and β sheets are shown as blue 





Figure 1.7: (Top) A ribbon diagram of Pa DDAH shown from orthogonal views; the 
view on the right is looking down the pseudo 5-fold axis into the active site pocket.  The 
color scheme is blue (N-terminus) to green to red (C-terminus).  (Bottom) A loop formed 
by residues 14-25 (shown in red) closes down over the active site when L-citrulline 
(black) is bound.  The main chain carbonyl of L18, which hydrogen bonds to the α-amino 
group of L-citrulline, latches the loop over the active site. 
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In addition to the Leu18 hydrogen bond, the α-amino and carboxylate groups of ADMA 
are also held in place by the carbonyl of Ile243 and the side chains of Arg132, Arg85, 
and Asp60, whereas the aliphatic portion of the molecule is flanked by the side chains of 
Phe63 and Leu161, shielding these methylene groups from the charged side chains 
occupying the active site [26] (Figure 1.8).  The guanidium portion of both ADMA and 
L-citrulline is anchored at the active site by the side chains of Asp66, which forms an 
ionic pair with HNε and HNω’, and Glu65, which forms an ionic pair with HNω’.   
The observation that the guanidium moieties of both the substrate, ADMA, and 
the product, L-citrulline, are bound in this manner suggests that the substrate is 
immobilized during catalysis.  Furthermore, these specific interactions clearly illustrate 
DDAH’s specificity for ADMA and NMMA, but not symmetric dimethyl-L-arginine 
(SDMA) (Figures 1.9 and 1.10).  Because one of the two ω amine groups in both ADMA 
and NMMA are not methylated, these NH2 groups can occupy the negatively charged 
hole formed by Glu66 and Asp65.  In contrast to this, SDMA, which has both of its ω 
amine groups methylated, cannot be accommodated at the active site since it’s docking 
would require the fitting of a HN-CH3 group in a negatively charged space where a H2N 
group is intended to fit, resulting in steric and electrostatic strain.   
A crystal structure of human apo-DDAH-1 (hDDAH-1) was recently solved in 
our laboratory to 2.0Å resolution.  Human DDAH-1 crystallized in the primitive 
monoclinic space group P21 with two monomers in the asymmetric unit [27].  The first 7 
residues of the N-terminus and the last 2 residues of the C-terminus are presumed to be 
disordered and hence, are not visible in the electron density maps [27].  The rms distance 
of equivalent Cα atoms of the non-crystallographic dimer was 0.16Å, indicating that the 
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two molecules of the asymmetric unit are virtually identical; the most significant 




Figure 1.8: The hydrogen bonding network of the active site of Pa DDAH.  The amino 
acid moiety is immobilized by hydrogen bonds to the side chain of D60 and the main 
chain carbonyls of L18 and I243, along with an ion pair to the side chains of R85 and 
R132.  The HNε and HNω groups are anchored by hydrogen bonds to the side chains of 
D66 and E65.  The β and γ methylene groups are flanked by F65 and L161, and the loop 




Figure 1.9: The structure of symmetric dimethyl-L-arginine (SDMA).  This compound 
cannot by hydrolyzed by DDAH, and is cleared by the renal system without further 












Figure 1.10: Recognition of ADMA substrate by DDAH.  The anionic hole created by 
the side chains of E65 and D66 is the mechanism by which DDAH discriminates between 
the substrates ADMA and NMMA and the non-hydrolyzable compound SDMA [26]. 
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The overall fold of hDDAH-1 was akin to the Pa structure, a barrel structure built from 
five ββαβ repeats arranged around a pseudo five fold axis (Figure 1.11 and 1.12).  A 
human DDAH-1●L-citrulline complex revealed that the methyl arginine substrate docks 
at the active site by a similar mechanism to the one seen with Pa DDAH [28] (Figure 
1.13).  In a similar mechanism to that seen with Pa DDAH, residues 25-38 form a loop 
structure that acts as a “lid” to close over the active site, with the main chain carbonyl 
group of residue L29, which is equivalent to L18 in Pa DDAH, acting as the “latch” 
(Figure 1.13).  The α-amino group of the substrate is anchored down by hydrogen 
bonding to the carboxylate side chain of Asp72, along with bonds to the main chain 
carbonyl groups of L29 and V267. (Figure 1.13)  The α-carboxylate group is held in 
place by an ion pair with the side chain of R144, while the aliphatic portion of the 
substrate is shielded from charged residues by the side chain of F75 (Figure 1.13).  As 
would be expected from the Pa structure, the hDDAH●L-citrulline complex showed that 
the carboxylate side chain of D78 participates in immobilizing the guanidinium moiety of 
the substrate (Figure 1.13).   
The core structure of Pa DDAH was found to be analogous to two other arginine 
modifying enzymes, arginine:glycine amidinotransferase and L-arginine:inosamine-
phosphate amidinotransferase, and these three structures are representative of a 
superfamily of arginine modifying enzymes [26].  Based on the correlation between these 
enzymes, it was proposed that the active site residues Cys249, His162, and Glu114 
constitute a catalytic triad that DDAH uses for catalysis [26].  These residues correspond 
to Cys273, His172, and Asp126 in human DDAH-1.  A mechanism was proposed for 
DDAH that initiates with the carbon of ADMA being nucleophilicly attacked by the γS 
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atom of Cys249, which had been activated by a preformed ion pair between Cys249 and 
His162 [26].  The tetrahedral intermediate is then hydrolyzed to form L-citrulline and 





Figure 1.11: Structure of human DDAH.  A cartoon structure figure of hDDAH-1 
showing the propeller formed by the five ββαβ repeats of the enzyme.  This view is 
looking down the pseudo 5-fold axis into the active site pocket.  α-helices are shown as 










Figure 1.12: A ribbon diagram of hDDAH-1 from orthogonal views.  The view on the 
right is looking into the active site pocket.  The color scheme is blue (N-terminus) to 











Figure 1.13: The hydrogen bonding network at the active site of hDDAH-1.  The α-
amine group of L-citrulline is hydrogen bonded to the main chain carbonyls of L29 and 
V267, in addition to the side chain of D72.  F75 stacks against the β and γ methylene 
groups.  The guanidinium moiety is covalently bound by the γS of C273 and the 
carboxylate side chain of D78.  The loop consisting of amino acids 25-38 (yellow) closes 
down over the active site.   
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Enzymatic studies by Stone et al confirmed that Cys249 is the active site 
nucleophile and that the mechanism proceeds through an S-alkylthiouronium 
intermediate, consistent with the mechanism proposed for other members of this 
superfamily (Figure 1.14) [29].  Furthermore, another study by this laboratory 
demonstrated that the role of His162 is not to activate the nucleophilicity of the γS of 
Cys249, but to act as a proton donor and acceptor at different stages of the reaction 
mechanism (Figure 1.14) [30].   
Incubation of a H162G Pa DDAH mutant with S-methyl-L-thiocitrulline (SMTC) 
resulted in the formation of a stable S-alkylthiouronium-DDAH adduct that does not 
hydrolyze [30].  Additionally, incubation of the mutant enzyme with Nω,Nω-dimethyl-L-
arginine did not result in the formation of a covalent intermediate [30].  Since protonation 
of the leaving group would be required for SMTC but not for ADMA, these observations 
indicated that His162 does not participate in a preformed ion pair with Cys249, but 
instead is responsible for protonating the leaving group in the first step of the reaction.  It 
also activates the water nucleophile that will hydrolyze the S-alkylthiouronium 
intermediate in the second step of the reaction [30].  This observation seems to be in 
agreement with the crystal structure since His162 is positioned a relatively distant 6Å 
from Cys249, and the substrate actually docks in between these two residues [30] (Figure 
1.15).  Therefore, the observed data suggested a substrate-assisted mechanism where the 
active site nucleophile, the γS of Cys249, is deprotonated and subsequently activated by 
the binding of a positively charged substrate, and the active site His162 has dual role in 
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protonating the substrate’s leaving group and activating a water molecule for hydrolysis 







Figure 1.14: The mechanism of the hydrolysis reaction catalyzed by DDAH.  Once 
ADMA or NMMA has docked, the reaction initiates with the nucleophilic attack by the 
γS of C249 on the ζC of the substrate to produce an S-alkylthiouronium intermediate.  
Dimethylamine or methyl amine serves as the leaving group.  A water molecule is then 
activated by H162 to hydrolyze the covalently bound intermediate, producing L-






Figure 1.15: Positioning of H162 and C249 in Pa DDAH.  In the Pa DDAH structure the 
side chain of His162 is positioned ~6.0Å away from C249, with the ligand docking 
between these two residues, making it unlikely that the two side chains participate in a 




DDAH Regulation and Inhibition 
 
Because DDAH contains a reactive cysteine residue, it was proposed that the 
enzyme may be regulated in vivo by S-nitrosylation [31].  Wild type Pa DDAH was 
found to be inactivated by NO donors in vitro, with activity being restored by the addition 
of dithiothreitol (DTT) [31].  Furthermore, a C249S site-directed mutant was not 
nitrosylated, confirming that the active site Cys is the residue being modified [31].  It was 
concluded that inactivation of DDAH in this manner represents an in vivo feedback 
mechanism whereby rising levels of NO lead to S-nitrosylation and subsequent 
inactivation of DDAH [31].  As a result of this feedback mechanism, levels of ADMA 
would increase and inhibit NOS, retarding the synthesis of NO.  Furthermore, it has also 
been discovered that Zn(II) can act to inhibit mammalian and Pa DDAH activity, and 
Stone et al confirmed that the Zn(II) metal ion chelates to the Cys249 and His162 active 
site residues of Pa DDAH, inactivating the protein (Figure 1.14).   
Overproduction of NO has been identified in practically every organ system as the 
cause of several pathophysiological changes, and reduction of NO production from iNOS 
is desirable to combat pathophysiological conditions such as septic shock, inflammatory 
pain, arthritis, and asthma [5].  Furthermore, NO production at low levels has been 
associated with the growth of a myriad of cancers, most likely due to the angiogenic 
properties of the compound [8].  As a result of these findings, compounds that inhibit NO 
production, by inhibiting NOS, DDAH-1, or both of these enzymes, may prove useful as 
anticancer drugs [27].  However, because of specific properties of the two proteins along 
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with the tissue specific isoforms that exist for both enzymes, designing effective drugs 
that inhibit NO production seems to be a complex problem [27].   
Although some success has been achieved with the design of compounds that 
selectively inhibit different isoforms of NOS, compounds that inhibit both NOS and 
DDAH seem to be the most attractive drug candidates since they would be consistent 
with a “kill two birds with one stone” approach to inhibiting NO production [27].  Leiper 
et al solved an enzyme●inhibitor complex of DDAH-1 and L-257, a methyl arginine 
analog that inhibited DDAH-1 with a sub 25μM IC50 [28].  Although, L-257 bound with 
some similarity to the L-citrulline structure some significant differences at the active site 
were observed (Figures 1.16 and 1.17).  Consistent with the model seen with L-citrulline, 
the flexible loop made by residues 25-38 folds down over the active site with the 
carbonyl of Leu29 hydrogen bonding to the α-amino group, which is also bound by 
hydrogen bonds with Val267 and Asp72.  Additionally, hydrophobic stacking is observed 
with the side chain of Phe75 and two of the nitrogens of the guanidino moiety are 
recognized by Asp78.  However, unlike the docking model seen in the L-citrulline 
structure, the inhibitor is bound in a “bent” conformation and the side chain of Arg144 is 
rotated away from the active site and does not form an ion pair with the α-carboxylate 
group of L257 [28].  Furthermore, at the guanidino portion of L-257, the side chain of 
Glu77 does not recognize the unsubstituted NH2 group, an interaction that was observed 
in the L-citrulline structure.  Perhaps the most striking difference between these two 
structures is the position of His172, which has rotated further away from the bound 




Figure 1.16: The hDDAH-1●L-257 complex.  The carboxylate side chain of D72, along 
with the main chain carbonyls of L29 and V267 anchor the α-amino and α-carboxylate 
groups of L-257.  D78 acts to hydrogen bond to the HNε and HNω groups of L-257’s 
guanidine moiety.  F75 stacks against the β and γ methylene carbons of the inhibitor, and 





Figure 1.17: Alignment of hDDAH-1●L-citrulline and hDDAH-1●L-257 structures.  A 
super imposition of the active sites of DDAH-1 with the ligands L-citrulline (green) and 
L-257 (blue) illustrating the differences in the positions of the side chains of R144 and 
H172.  When L-257 is bound, R144, which hydrogen bonds to L-citrulline’s carboxylate 
group, is observed to be facing away from the ligand, and H172 has tilted away from the 





Fast and coworkers assayed for DDAH-1 inhibition by known NOS inhibitors 
belonging to three different classes of compounds: S-alkyl isothioureas, 
aminoguanidines, and amidines.  Although the S-alkyl isothioureas and the 
aminoguanidine compounds were not inhibitors, the amidino class of compounds did 
show some promise as a scaffold for a dual-targeted inhibitor since one of these 
compounds, N5-(1-iminoethyl)-L-ornithine (L-NIO) inhibited DDAH-1 weakly (KI = 
990μM) [27] (Figure 1.18).   
Secondary inhibition experiments using the alkyl-substituted amidines N-(1-
iminopropyl)-L-ornithine (L-IPO), N-(1-iminopentyl)-L-ornithine (L-IPnO), and N-(1-
iminohexyl)-L-ornithine showed that inhibition of DDAH-1 depended in some part on 
the length of the alkyl substituent [27].  The inhibitor L-IPO, which is one methylene 
group longer than L-NIO, proved to be a 20-fold stronger inhibitor of DDAH-1 than L-
NIO [27].  Furthermore, L-IPnO, which is two methylenes longer than L-IPO and three 
methylenes longer than L-NIO, displayed 7-fold stronger inhibition over L-IPO [27].  
However, further extension of the alkyl substituent does reach a tipping point as L-IPnO 
proved to be a more effective inhibitor than N-(1-iminohexyl)-L-ornithine [27].  
Branching of the alkyl substituent did not augment inhibition as N-(1-iminoisobutyl)-L-
ornithine has a KI value on the same order as L-IPO [27].  Interestingly, whereas 
extension of the alkyl chain resulted in higher inhibitor potency between L-NIO, L-IPO, 
and L-IPnO, it had the opposite effect on NOS inhibition as extending L-IPO into N-(1-
iminohexyl)-L-ornithine resulted in a greater than 1000-fold decrease in inhibition of 
NOS (this resulted in only a two-fold decrease in inhibition for DDAH-1) [27].  
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Figure 1.18: Inhibitors of hDDAH-1.  L-NIO, L-IPO, L-IPnO, and N-(1-iminodexyl)-L-
ornithine are inhibitors of human DDAH-1 belonging to the guanidinium class of 
compounds.  Extending the ethyl alkyl chain of L-NIO to a pentyl alkyl chain increased 




The Fast group studied the inhibition of hDDAH-1 by L-IPO in further detail 
using solution NMR and site-directed mutagenesis.  In collaboration with our group, the 
hDDAH-1●L-IPO complex was crystallized in the space group P21 with two molecules 
in the asymmetric unit.  This enzyme-inhibitor complex was solved to 1.9Å resolution.  
The first 4 residues of the N-terminus and the last 3 residues of the C-terminus are not 
seen in the electron density map.  The Cα atoms of the hDDAH-1●L-IPO complex and 
the apo-hDDAH-1 are in similar positions (rms distance of 0.30Å).  From the hDDAH-
1●L-IPO X-ray structure it was found that L-IPO binds in essentially the same way as 
other DDAH-1 substrates, however, strong, continuous electron density extending from 
the γS of Cys274 to the C of L-IPO indicated that the enzyme●inhibitor complex 
crystallized as a covalent adduct (Figure 1.19 and 1.20) (Note: the numbering sequence 
for the hDDAH-1●L-IPO structure is advanced by 1, i.e. the active site nucleophile is 
Cys274 in this structure and Cys273 in the hDDAH-1●L-257 structure).   
Besides the covalent bond to the enzyme, the L-IPO inhibitor makes a hydrogen 
bond interaction between the carboxylate side chain of Asp73 and L-IPO’s α-amino 
group; the amino group is also recognized by the main chain carbonyls of Leu30 and 
Val268 (Figure 1.19).  The α-carboxylate of the inhibitor ion pairs with the side chain of 
Arg145, whereas the aliphatic chain hydrophobicly interacts with the side chains of 
Leu271 and Phe76 (Figure 1.19).  Consistent with the interactions participating in the 
docking of L-citrulline, the guanidinium group of L-IPO is recognized by Glu78 and 
Asp79 (Figure 1.19).   
Unlike the hDDAH-1●L-257 structure, the only significant difference in the 
position of active site residues was that of His173, which again is observed to be further 
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away from the bound L-IPO than it was from L-citrulline (Figure 1.21).  However, the 
side chain of Arg145 was observed to form an ion pair to the α-carboxylate group, which 
was not observed in the DDAH-1●L-257 structure.   
The contributions of a subset of these interactions to L-IPO docking were 
investigated by site-directed mutagenesis in the Fast laboratory.  An E78A mutation 
reduced the energy of L-IPO docking by 1.9 kcal/mole [27].  Although salt bridges of this 
type usually contribute 3-4 kcal/mole to the stabilization energy, this lower value was 
expected since Glu78 also forms a salt bridge with Lys175 [27].  A L271G mutation 
reduced the stabilization energy of binding by 1.0 kcal/mole, completely consistent with a 






Figure 1.19: The docking of L-IPO at the active site of hDDAH-1.  The amino acid 
moiety of L-IPO is bound by ion pairing to R145 along in addition to hydrogen bonding 
with the side chain of D73 and the main chain carbonyls of L30 and V268.  The 
guanidine moiety is hydrogen bonded to the carboxylate side chains of D79 and E78 in 
addition to a covalent linkage between the ζC of L-IPO and the γS of C274.  The loop 





Figure 1.20: The Fo-Fc difference map for the hDDAH-1●L-IPO complex.  The Fo – Fc 
map at a 3σ contour showing continuous, strong electron density extending between the 
γS atom of C274 and the ζC of L-IPO, indicative of a covalent linkage between the two 




Furthermore, when the Leu30 “latch” was mutated to alanine, a reduction in L-
IPO inhibition was also observed, indicating that flap closure makes some contribution to 
inhibitor binding, as it does with substrate binding.  However, no major secondary 
structure rearrangements appear to occur as measure by a lack of significant changes in 
the circular dichroism spectrum [27].   
Although the crystal structure showed that L-IPO inhibited through the formation 
of a covalent adduct, additional experiments showed that the mode of inhibition is not 
irreversible since mass spectrometry did not detect any covalent adducts and activity 
could be restored by diluting into inhibitor free buffer [27].  Furthermore, the possibility 
that L-IPO is a non-ideal substrate for DDAH-1, and by default, an inhibitor, was also 
dismissed since no hydrolysis of L-IPO was detected [27].  Because a covalent or 
noncovalent complex could not be detected by 13C NMR experiments, it was concluded 
that L-IPO is basically a competitive inhibitor that acts to form a non-hydrolyzable 
tetrahedral adduct via the linkage of the γS of Cys274 (which is designated as Cys273 in 
the hDDAH-1●L-citrulline and hDDAH-1●L-257 structures) and the ζC of L-IPO.  This 
bond is very weak and the reversibility of inhibition is due to the formation and cleavage 
of the bond being in rapid equilibrium [27].  It is important to point out that other 
enzymes that use Cys as a nucleophile also form reversible covalent adducts, and 
specifically, arginine deiminase, another member of the pentein superfamily, has been 
observed to form a tetrahedral enzyme-inhibitor adduct [27].   
When one compares the structure of native hDDAH-1 with the L-IPO, L-
citrulline, and L-257 structures some variation in the positioning of active site residues 
and even flexibility in the ligand conformation has been observed (Figure 1.17 and 1.21).  
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Between these four structures, His173 (which is designated as His172 in the hDDAH-
1●L-citrulline and hDDAH-1●L-257 structures), a direct participant in the enzymatic 
mechanism, is in closest proximity to the ligand in the hDDAH-1●L-citrulline structure.  
The loop consisting of residues 169ADGL172 is ordered in the native and L-IPO structures, 
it is disordered in the L-citrulline and L-257 structures [27]. 
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Figure 1.21: A superimposition of hDDAH-1●L-citrulline (green) and hDDAH-1●L-
IPO (blue).  The loop preceding H173 in the L-IPO structure, consisting of residues 
169ADGL172 is ordered in this structure and disordered when L-citrulline is bound, 
however, H173 is not positioned as far away from the L-IPO ligand than it was from the 
L-257 ligand. Note: the hDDAH-1●L-IPO sequence is advanced by one compared with 
other hDDAH-1 sequences i.e. the active site His is H173 for this structure.  
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The hDDAH-1●L-IPO structure demonstrated that alkyl substituted amidines are 
promising scaffolds for the design of dual target therapeutics that can control NO 
production, since these compounds can effectively inhibit both NOS and DDAH-1; it 
appears that the alkyl substituent may determine which of the two enzymes it is more 
specific for.  Although these initial inhibition studies with alkyl substituted amidines 
yielded encouraging results, further structural studies of hDDAH-1-amidine complexes 
are warranted.  In particular, we want to address why inhibition at least partially depends 
on alkyl chain length, for the design of more potent DDAH-1/NOS inhibitors.   
In addition to the substituted amidines, the Fast laboratory has reported that 
ebselen, a selenium containing compound, inhibits DDAH-1 with an IC50 of 300nM 
(Figure 1.22).  The inhibition seems to be irreversible since dilution into inhibitor free 
buffer did not restore activity, in contrast to the case with L-IPO inhibition.  It is believed 
that ebselen’s mode of inhibition is to form a covalent adduct with either Cys273 or 
His172.  Ebselen is the most potent DDAH-1 inhibitor to date and represents a new 
scaffold for future design of DDAH-1 inhibitors.  An X-ray structure of the DDAH-











Because of its role in a litany of pathophysiological states, cellular nitric oxide 
production, specifically, regulation of NO production through the selective inhibition of 
NOS and DDAH is an area of intense research.  However, at the onset of this research 
project only three known hDDAH-1●inhbitor structures existed and represented a small 
pool of structural information from which to design more effective inhibitors for this 
enzyme.  As a collaborative effort with the Fast research group (The University of Texas 
at Austin), the goals of this project were to crystallize and solve the structure for enzyme 
inhibitor complexes of hDDAH-1 with the compounds L-IPnO and ebselen.  These 
structures presented in this study contribute important information that allows for the 
progress of drug design in this research field.           
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Plasmids containing the human DDAH-1 gene cloned into pET28a (Novagen, 
Madison, WI) were generously provided by the Fast laboratory (University of Texas at 
Austin, Austin, TX).  Ni-NTA His-Bind® resin was obtained from Novagen (Madison, 
WI).  The pre-packed HiLoad 16/60 Superdex S-200 prep grade column was obtained 
from GE healthcare (Piscataway, NJ).       
      
Methods 
 
Expression and purification of recombinant hDDAH-1 
 
The pET28a-DDAH isoform 1 (H. sapians) vector was transformed into E. Coli 
strain Rosetta 2 (DE3) under the dual selection of kanamycin and chloramphenicol.  The 
285aa ORF encodes a 6X His●Tag fused to the N-terminus.  Fresh transformants were 
grown in Terrific Broth media (Difco) at 37 °C until reaching an optical density of 0.7.  
Upon reaching this OD the hDDAH-1 protein was expressed by the addition of isopropyl 
β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1mM.  Cells were 
allowed to grow for another 3 hours post induction, and were harvested by centrifugation 
at 4000g for 10 minutes.  Cells were resuspended in lysis buffer (25mM Tris-HCl pH 8, 
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250mM NaCl) and run through a French Pressure cell 3 times at 1000 PSI.  Cell debris 
was removed by centrifugation at 30,000g for 1 hour and the crude cell lysate was passed 
though a column packed with Ni-NTA His-Bind® resin.  The column was washed with 
500 mL of a 25 mM Tris-HCl pH 8, 250mM NaCl, 10mM imidazole buffer and the 
heterocomplex was eluted with a linear gradient from 10 – 250mM imidazole.  Protein 
containing fractions were pooled together and dialyzed against a 10 mM Tris-HCl 50 mM 
KCl buffer and concentrated.  The recombinant hDDAH-1 was further purified by gel 
filtration using a HiLoad 16/60 Superdex S-200 prep grade column and an AKTA FPLC 
system (GE Healthcare, Piscataway, NJ).  The protein was loaded onto the S-200 column 
that had been previously equilibrated with a 10mM Tris-HCl pH 8, 50mM KCl buffer 
and run through the matrix at a flow rate of 1mL/min.  Protein containing fractions were 




Figure 2.1: A 12% SDS PAGE gel of hDDAH-1 purified by gel filtration on a Superdex 
S-200 column.  Lane 1: Molecular weight standards, Lane 2: Eluted A280 peak containing 











Crystallization of hDDAH-1●L-IPnO and hDDAD-1●ebselen 
complexes 
 
The purified hDDAH-1 protein was concentrated to 15-17mg/mL, as determined 
by OD280 absorption readings and Beer’s Law: 
 




C = the protein concentration (mg/mL) 
A = the absorption at 280nM 
ε = the extinction coefficient of hDDAH-1; calculated as 0.30 (mg/mL)-1cm-1  
b = the cuvette pathlength, 1cm 
 
The best quality hDDAH-1 crystals were grown from a mother liquor of 0.1M 
Tris-HCl pH 8.2, 20% polyethylene glycol 6000 (Figure 2.2).  Briefly, crystal drops were 
set up using the sitting drop method by combining 3 μL of the hDDAH-1 sample with 3 
μL of mother liquor in a VDX crystallization plate (Hampton Research, Aliso Viejo, 
CA), sealed with tape, and allowing the drop to equilibrate at 4 °C.  Crystals for the 
enzyme●inhibitor complexes of hDDAH-1●L-IPnO and hDDAH-1●ebselen were 
obtained by separately adding corresponding volumes of stock solutions of L-IPnO and 
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ebselen to crystal containing drops to yield final concentrations of 150μM and 480μM 
respectively, and allowing re-equilibration overnight.   
 
Cryo-cooling and Data collection of hDDAH-1●L-IPnO and 
hDDAH-1●ebselen crystals 
 
The hDDAH-1●L-IPnO and hDDAH-1●ebselen crystals were removed from the 
sitting drop using a nylon loop, soaked in a 0.1M Tris pH 8.2, 35% polyethylene glycol 
6000 solution, and flash frozen in liquid nitrogen.  The crystals were then mounted for 
data collection.   
 
Data processing of hDDAH-1●L-IPnO and hDDAH-1●ebselen 
crystals   
 
Data collected for both enzyme●inhibitor complexes were processed using 
HKL2000 suite [32].  XDISPLAYF was first employed to display raw x-ray diffraction 
data as images and identify diffraction maxima for each of the two enzyme●inhibitor data 
sets.  DENZO was then used to index the reflection intensities and cell refinement of each 
of the two data sets.  SCALEPACK was used to scale and merge the data.  Both enzyme 
inhibitor complexes belong to the primitive monoclinic space group P21.  The hDDAH-
1●LIPnO had the cell constants a = 47.21Å, b = 80.90Å, c = 74.09Å, α = 90, β = 90.13, γ 
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= 90.  The hDDAH-1●ebselen crystals had the cell constants of a = 47.501Å, b = 





Figure 2.2: DDAH-1 crystals.  The best quality crystals were grown from a mother 










Molecular replacement     
 
Molecular replacement solutions for the hDDAH-1●L-IPnO and hDDAH-
1●ebselen data were executed using hDDAH-1 as the search model.  Structure factors for 
both enzyme●inhibitor complexes were calculated using CCP4 [32] and input into 
PHASER (CCP4 suite) to produce the initial 2Fo-Fc and Fo-Fc electron density maps and 
preliminary hDDAH-1 coordinates. 
 
Model Building and Refinement 
 
The hDDAH-1 models for both enzyme●inhibitor complexes were fit to the 2Fo-
Fc and Fo-Fc maps using COOT [33] at a 1σ and 3σ level contours, respectively.  The 
apo-DDAH-1 structures were built using COOT, and the functional coordinate, 
parameter, and topology data for both inhibitors were made using the PRO DRUG 
SERVER [34].  The inhibitors were then modeled into their respective electron density 
maps using COOT.  The hDDAH-1●L-IPnO and hDDAH-1●ebselen structures were run 
through several rounds of refinement using CNS and PHENIX [35].  Because PHENIX 
determined that the hDDAH-1●ebselen data were twinned, this data had to be further 
processed using PHENIX and CCP4 to detwin the data.  For refinement of both 
enzyme●inhibitor complexes, non-crystallographic symmetry restraints were used.  The 
positions of ordered water molecules in the hDDAH-1●ebselen structure were predicted 





The phi and psi angle compatibility of the models was assessed using 
PROCHECK.  The DDAH-1●IPnO model had 86.3% of its residues in the most 
favorable regions of the Ramachandran plot, with 12.7% lying in additional allowed 
regions and 1% lying in generously allowed regions with no residues having disallowed 
phi and psi conformations.  The DDAH-1●ebselen model had 81.3% of its residues in the 
most favorable regions of the Ramachandran plot, with 15.8% lying in additional allowed 
regions and 2.9% lying in generously allowed regions with no residues having disallowed 
phi and psi conformations.   
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Chapter 3: Results and Discussion 
 
Structure of the hDDAH-1●L-IPnO Complex 
 
The structure of the DDAH-1●IPnO complex was solved to 2.9Å resolution.  The 
enzyme inhibitor complex crystallized in the primitive monoclinic space group P21 with 
cell constants a = 47.21Å, b = 80.90Å, c = 74.09Å, α = 90, β = 90.13, γ = 90 and 2 
DDAH-1 molecules in the asymmetric unit (Table 3.1).  The Vm of the enzyme●inhibitor 
complex is 2.3Å3 /Dalton.  Residues 1-7 and 282-285 were not observed in the electron 
density maps and are believed to be flexible parts of the protein.  Additionally, electron 
density was not observed for residues 32 and 33, which form part of the flexible loop that 
closes over the active site, and hence these were not built into the model.   
The initial round of model building and refinement was carried out without the L-
IPnO inhibitor; this minimizes phase bias while the model is still unrefined.  As was the 
case with L-IPO inhibition, the initial difference maps revealed density extending from 
the γS atom of Cys273 to the ζC of the guanidinium moiety of L-IPnO (Figure 3.2).  
Because very strong, continuous difference density was observed between these two 
atoms the enzyme inhibitor complex was built as a covalent adduct.   
It is important to note that covalent attack by the γS nucleophile of Cys273 
generates a stereocenter at the ζC of L-IPnO.  Because of the modest resolution limits of 
the structure, both R and S configurations of the DDAH-1●L-IPnO structure can be 
modeled into the electron density.  However, the density for the covalent bond, and the 
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amino acid portion of the inhibitor were clear and unambiguous (Figure 3.2).  The other 
groups bonded to the ζC atom are the alkane group and the guanidinium group.  Steric 
constraints and electrostatic interactions made this assignment very straightforward.  In 
particular, the R conformation puts both of the inhibitor’s guanidino NH groups in a 
favorable hydrogen bonding position with Asp78 (Figure 3.4).  Furthermore, the 
homologous enzyme●inhibitor structure between DDAH and L-IPO was built in the R 
configuration using much higher resolution data that clearly shows the position of the –
NH2 and –CH2CH3 groups in addition to chemical evidence implicating this 
configuration (Figure 3.3).   
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Table 3.1: Crystallographic Data for the hDDAH-1●L-IPnO Complex 
 
 hDDAH-1●L-IPnO 
Space group P21 
Cell constants a = 47.21Å, b = 
80.9Å, c = 74.09Å, β = 
90.13° 
Resolution (Å) (outer shell) 20 – 2.9 (2.90-2.95) 
Rmerge (%) (outer shell) .113 (.338) 
<I/σI> (outer shell) 12.2 (5.1) 
Completeness (%) (outer shell) 95.4 (100.0) 
Unique reflections 11935 
Redundancy 3.4 
# of residues 548 
# of protein atoms 4184 
# of ligand atoms 30 
# of solvent atoms -- 
Rworking 0.2153 
Rfree 0.3154 
Average B factor for protein atoms (Å2) 36.42 
Average B factor for ligand atoms (Å2) 37.48 
Average B factor for solvent atoms (Å2) -- 
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rms deviation from ideality 
     bonds (Å) 




Ramachandran plot  
  % of residues in most favored region 86.3 
  % of residues in additional allowed region 12.7 




Figure 3.1: Crystal packing of the hDDAH-1●L-IPnO complex.  The enzyme●inhibitor 
complex crystallized in the P21 space group (the green box represents the unit cell 












Figure 3.3: The Fo-Fc electron density map for the hDDAH-1●L-IPO complex.  The 
electron density clearly shows the ζC atom of the inhibitor in R orientation with the ε and 
ω amine groups hydrogen bonded to the carboxylate side chain of D79.  This figure was 
made at a 3σ level contour (Note: the numbering of the residues for the hDDAH-1●L-
IPO complex is advanced by one, i.e. D79 in this complex is equivalent to D78 in the 







Figure 3.4: Stereochemical orientation of L-IPnO.  The 2Fo – Fc map at a 1σ contour 
showing the carboxylate side chain of Asp78 hydrogen bonding to the HNε and HNω 







In addition to the covalent bond to Cys273 and the hydrogen bonding with Asp78, the L-
IPnO inhibitor is also docked into the active site via hydrogen bond contacts with 
Arg144, Arg97, Glu77, Asp72, Leu29, and Val267 (Figure 3.5).  Glu77 ion pairs with 
Lys174 to form the “bottom” of the active site, and also hydrogen bonds with L-IPnO’s 
primary amine group.  The guanidino groups of the Arg144 and Arg97 side chains make 
hydrogen bond contacts with the α-carboxylic acid group, whereas the side chain of 
Asp72 makes a salt bridge with L-IPnO’s α-amino group.  The main chain carbonyls of 
both Leu29 and Val267 make hydrogen bond contacts with L-IPnO’s α-amino group.  
The Leu29 contact is of particular note since this residue represents the snap closure of 
the active site “lid” formed by amino acids 25-38, with the Leu29 side chain covering the 
active site channel.  The β and γ methylene groups of L-IPnO are flanked on one side by 
the aromatic side chain of Phe75 (Figure 3.6).  As expected the loop formed by amino 
acids 25-38 is in the closed conformation in this structure, as has been observed for 
DDAH-1 in complex with other ligands including L-citrulline, L-homocysteine, and S-
nitroso-L-homocysteine, and the hydrogen bond contacts and other interactions used for 
docking L-IPnO are identical to those used for docking L-IPO and L-citrulline.   
At the dimer interface, crystal packing interactions are made by hydrogen bonding 
between Glu36 of one molecule and Arg98 of another and Ser96 of one molecule and 
Asp38 of another (Figure 3.7).  Furthermore, hydrophobic packing between the side 
chain of Leu29 and Ala40 also occurs at the crystal packing interface.  As one would 
predict from the structural similarity, the hDDAH-1●L-IPO and hDDAH-1●L-IPnO are 
virtually identical with an rms distance for all atoms of 0.40 Å.  In both crystal structures, 
the α-carboxylate group of the inhibitor is hydrogen bonded to the guanidinium side 
 65
chain of Arg144 while the α-amino group is docked by the main chain carbonyls of 
Leu29 and Val267 along with the side chain of Asp72.  Both L-IPO and L-IPnO’s 
methylene carbons are flanked on one side by the aliphatic side chain of Phe75, and the 
guanidino amine groups of both inhibitors form a salt bridge with Glu77 and Asp78.  The 
similarity of these interactions would be expected since the two inhibitors differ only in 
the length of their alkyl side chains.  L-IPnO was shown to be a 7-fold stronger inhibitor 
than L-IPO, however, the only structural basis that supports this kinetic data is that L-
IPnO’s pentyl alkyl chain may make stronger interactions with the side chain of L270 




Figure 3.5: The hydrogen bonding network of the hDDAH-1●L-IPnO complex.  The 
amino acid portion of the compound is anchored by hydrogen bonds to the side chains of 
R97 and R144 along with the main chain carbonyls of L29 and V267.  The ζC atom of 
the guanidinium moiety is covalently linked to C273 and the HNε and HNω groups are 











Figure 3.6: Hydrophobic interactions in the hDDAH-1●L-IPnO complex.  The aromatic 
ring of F75 stacks onto the β and γ methylene groups of L-IPnO.  The side chain of L270 




Figure 3.7: Intermonomer interactions in the hDDAH-1●L-IPnO complex.  A salt bridge 
at the dimer interface of the hDDAH-1●L-IPnO complex between E36 of one hDDAH-1 
monomer of the asymmetric unit (green) and R98 of the other (blue).  
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Figure 3.8: A superimposition of hDDAH-1●L-citrulline (green) and hDDAH-1●L-
IPnO (blue).  Similar to the L-IPO structure, the loop preceding H172 in the L-IPnO 
structure, consisting of residues 169ADGL172 is ordered in its structure and disordered 
when L-citrulline is bound.  As was the case with L-257, H172 is positioned further away 
from the L-IPnO ligand than the L-citrulline ligand.   
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Figure 3.9: A superimposition of hDDAH-1●L-IPO (orange) and hDDAH-1●L-IPnO 
(blue).  The main difference between the two structures is the positioning of the H172 
side chain, which is in closer proximity to the ligand in the L-IPO structure than in the L-










Structure of the hDDAH-1●ebselen Complex 
 
The structure of the hDDAH-1●ebselen complex was solved to 2.0Å resolution.  
The hDDAH-1●ebselen complex crystallized in the primitive monoclinic space group 
P21 with cell constants a = 47.501Å, b = 81.05Å, c= 74.013Å, α= 90.00, β = 90.11, and γ 
= 90.00 (Table 3.2).  The structure has 2 molecules in the asymmetric unit and a Vm = 
2.3Å/dalton.  The initial difference maps only showed a small, albeit dense, blob of 
electron density around Cys273 (Figure 3.11).  This led to an analysis of the problem that 
ultimately revealed the crystal exhibited pseudomerohedral twinning.  The program suite 
PHENIX is able to refine the twinning parameters, which showed a 73%- 27% ratio.   
After detwinning the diffraction data and several rounds of refinement using 
PHENIX, the density for the inhibitor became visible (Figure 3.12).  The major point is 
that strong density is seen running continuously from the γS of Cys 273, to the selenium 
atom of ebselen, suggesting that a covalent bond has been formed between these two 
atoms (Figure 3.12).  This enzyme-inhibitor complex also has the flexible loop made up 
of residues 25-38 in the closed conformation (Figure 3.13).  This flap closure is a 
particularly interesting observation since ebselen lacks an α-amino group to which L29 
can hydrogen bond to and “latch” the active site shut.  The isobutyl groups of Leu29 and 
L270 and the aromatic ring of Phe75 act to hydrophobicly stack onto both of ebselen’s 
phenyl rings (Figure 3.14).  Crystal packing interactions at the hDDAH-1●ebselen dimer 
interface include hydrogen bonding between Glu36 of one molecule, a water molecule, 
and Arg98 of another molecule (figure 3.15).  Other crystal packing interactions include 
hydrogen bonding between Asp38 and Ser96.     
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Because Fast and coworkers were the first to study the inhibition of hDDAH-1 by 
ebselen, some important details of the inhibition were unknown.  Specifically, it had not 
been determined whether the compound inhibited hDDAH-1 by attacking Cys273 or 
His172.  Covalent modification of C273 has been observed with several compounds 
including L-IPO and L-IPnO.  However, inhibition by attack of His172 was also 
observed with the inhibitor, 4-hydroxynonenal (4-HNE).  From the hDDAH-1●ebselen 
electron density maps it is clear that ebselen’s mode of inhibition is covalent attachment 
to C273 via a selenyl-sulfide bond (Figure 3.16).    
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Table 3.2: Crystallographic Data for the hDDAH-1●ebselen Complex 
 
 hDDAH-1●ebselen
Space group P21 
Cell constants a = 47.501Å, b = 
81.05Å, c = 74.013Å, β = 
90.11° 
Resolution (Å) (outer shell) 20-2.0 (2.07-2.11) 
Rmerge (%) (outer shell) .076 (0.418) 
<I/σI> (outer shell) 10.3 (4.5) 
Completeness (%) (outer shell) 96.9 (99.2) 
Unique reflections 33141 
Redundancy 3.6 
# of residues 548 
# of protein atoms 4184 
# of ligand atoms 32 
# of solvent atoms 230 
Rworking .1804 
Rfree .2871 
Average B factor for protein atoms (Å2) 37.65 
Average B factor for ligand atoms (Å2) 45.93 
Average B factor for solvent atoms (Å2) 33.34 
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rms deviation from ideality 
     bonds (Å) 




Ramachandran plot  
  % of residues in most favored region 81.3 
  % of residues in additional allowed region 15.8 
  % of residues in generously allowed region 2.9 
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Figure 3.10: Crystal packing of the hDDAH-1●ebselen complex.  The hDDAH-
1●ebselen complex crystallized in the P21 space group.  The unit cell dimensions are 




Figure 3.11: The Fo-Fc difference map for the hDDAH-1●ebselen complex.  The Fo – 
Fc map at a 3σ contour showing strong electron density extending from the γS of C273, 






Figure 3.12: The hDDAH-1●ebselen electron density map.  The 2Fo-Fc map at 1.5σ 








Figure 3.13:  Loop closure in the hDDAH-1●ebselen complex.  The flexible loop made 
up of residues 25-38 folds over the active site.  However, the main chain carbonyl of L29 






Figure 3.14: Hydrophobic interactions at the active site of the hDDAH-1●ebselen 
complex.  The side chains of L29, F75, and L270 are involved in hydrophobic stacking 




Figure 3.15: A hydrogen bonding network at the dimer interface of the hDDAH-
1●ebselen structure.  E36 of one chain (green) hydrogen bonds with a water molecule 










Figure 3.16: Inhibition of DDAH-1 by ebselen.  Ebselen’s selenium atom reacts with the 




 Ebselen has a completely different structure from the arginine analogs that have 
previously been crystallized with hDDAH-1.  In stark contrast to these ligands, the 
binding of ebselen almost exclusively involves covalent attachment to the active site 
cysteine.  However, for the most part, the positioning of the active site residues in the 
four hDDAH-1●ligand structures is the same, with the exception of H172, the loop 
preceding it, and R144.  With respect to these residues, the binding of ebselen to 
hDDAH-1 is quite different from the L-citrulline model (Figure 3.17).  R144, which ion 
pairs with the α-carboxylate group of L-citrulline, is facing away from the from the 
ebselen ligand.  Additionally, the backbone atoms of the loop preceding H172, deviate 
significantly (rms of 1.6 Å for 170GLH172) between these two structures.  Finally, when 
compared to the L-citrulline structure, the side chain of H172 has tilted away from the 
active site when ebselen docks.  Interestingly, the side chain of R144 in the L-257 
structure was also observed to be facing away from the active site and not involved in 
docking of the ligand (Figure 3.18).  Furthermore, the loop consisting of residues 
168ADGLH172 adopts a very similar conformation between the two structures (rms of 0.5 




Figure 3.17: hDDAH-1●ebselen aligned with hDDAH-1●L-citrulline.  A 
superimposition of the L-citrulline (green) and ebselen (blue) structures.  In contrast to 
the L-citrulline structure, the side chain of R144 points away from the active site in the 
ebselen structure.  Additionally, H172 has tilted away from the active site in the ebselen 




Figure 3.18: hDDAH-1●ebselen aligned with hDDAH-1●L-257.  A superimposition of 
the L-257 (yellow) and ebselen (blue) structures.  The docking of these two structures is 
similar.  In both cases the side chain of R144 points away from the active site and H172 




Chapter 4: Conclusion 
 
In this study, the crystal structures of hDDAH-1 complexed with L-IPnO and 
ebselen were solved to 2.9 Å and 2.0 Å resolution, respectively.  The L-IPnO inhibitor 
was shown to dock in essentially the same manner as the inhibitors L-IPO and L-257.  
This mode of docking, involves the closure of the flexible loop over the active site, 
hydrogen bond and ion pair interactions, hydrophobic interactions, and a covalent linkage 
between the ζC atom of the inhibitor and the γS atom of C273.  The L-IPnO structure did 
show some differences from these other two structures at the active site, specifically, the 
positioning of H172 with respect to the bound ligand.  L-IPnO was shown to be a more 
potent inhibitor than L-IPO and from the structural data presented here it can be 
concluded that this is most likely due to a more favorable hydrophobic interaction 
between the pentyl group of L-IPnO and the side chain of L270. 
The ebselen inhibitor was shown to bind to the enzyme almost exclusively by a 
covalent linkage between the inhibitor’s selenium atom and the γS of C273, with flap 
closure also occurring.  This crystal structure clearly showed that ebselen’s mode of 
inhibition is attack of C273, not H172.  Furthermore, although ebselen belongs to a 
completely different class of compounds than the L-arginine analog L-257, the binding of 
this compound to hDDAH-1 with respect to the conformation of R144 and the 
168ADLGH172 loop was found to be similar. 
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Chapter 5: Future Work 
 
Ebselen is the first seleno compound shown to inhibit hDDAH-1.  It is also the 
most potent inhibitor of this enzyme to date, with a reported IC50 of 300nM.  In addition 
to further expansion of the amidine scaffold, future work should concentrate on seleno 
compounds like ebselen as a promising scaffold for the design of potential inhibitors for 
hDDAH-1.         
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Chapter 6: Introduction 
 
Messenger RNA Trafficking in Neurons  
 
Cellular trafficking of mRNAs and localized protein expression are mechanisms 
by which cells spatially and temporally control gene expression [36].  By dictating when 
and where protein encoding mRNAs are translated in the cell, functionally distinct 
cellular compartments and structures can be established.  To perform this task, the cell 
must be able to transport localized mRNAs in a translationally dormant state and also be 
able to activate translation of the message once it has reached it’s destination.  This task 
is accomplished by the cell’s use of RNA binding proteins that target cis-regulatory 
sequences in the localized mRNA.  These trans-acting factors bind to their target 
mRNAs, forming a translationally dormant ribonucleoprotein complex that can interact 
with cytoskeletal motor proteins for transport to its subcellular destination (Figure 6.1) 
[37].  Once the mRNA cargo has been delivered, the translational repressor is inactivated 
and the message is released.  Neuronal cells are a paradigm for mRNA localization and 
spatial control of protein synthesis.  It has been observed that differentiated neurons 
stockpile mRNAs in their dendritic branches (Figure 6.2) [36].  By storing mRNAs in this 
manner, neurons can conduct localized translation of any subset of these mRNAs as a 
response to synaptic transmissions, a property that grants these cells their trademark 




Figure 6.1: RNA trafficking in neuronal cells.  In the nucleus, RNA binding proteins 
target localized mRNAs through recognition of cis-elements in the 3’ UTR.  These 
mRNAs are then exported to the cytosol and organized into translationally dormant 
ribonucleoprotein particles.  These RNPs are then transported by motor proteins along the 










Figure 6.2: A cartoon representation of a neuronal cell.  Electrochemical messages 
received from other neurons reach the soma, or central body, of the neuron via the 
synaptic junctions of the dendritic branches.  The axon of the neuron acts to send 
electrochemical messages away from the soma and out to other neurons.  It is known that 
neurons stockpile translationally dormant mRNAs, in the form of RNPs, in their dendritic 









mRNA Sorting During Spermatogenesis 
 
Mammalian male germ cell differentiation is another cellular process that 
employs post-transcriptional control to determine when and where gene expression 
occurs in the cell.  Spermatogenesis is the cellular process that transforms diploid 
testicular stem cells into mature spermatozoa [38].  In mammals, males are provided with 
a definitive number of testicular stem cells, estimated to be about 10,000, that provide 
fertility for the lifetime of the individual.  The cells that comprise this stem cell 
population will undergo one of three fates (Figure 6.3).  One subset of the population will 
undergo mitotic divisions to produce identical cells that replenish the cell line, whereas 
another subset will undergo apoptosis.  A third subset of these testicular stem cells, which 
comprises the majority, enter a differentiative pathway to become mature spermatozoa.  
Spermatogenesis initiates with mitotic divisions followed by meiotic divisions to produce 
secondary spermatocytes [38].  These secondary spermatocytes then undergo several 
morphological changes during spermiogenesis to produce mature elongated spermatozoa.  
It is during spermiogenesis that the spermatocyte nucleus becomes transcriptionally silent 
due to the protein component of chromatin being exchanged twice; first histones are 
replaced by transition proteins and then transition proteins are replaced by testis specific 
proteins called protamines [38].   
Because transcription terminates mid way through spermiogenesis, post-
transcriptional regulation of protein expression takes on a particular prominent role 
during this stage of spermatogenesis [38].  Specifically, proteins needed in the final 
stages will have to be transcribed prior to termination of transcription and these messages 
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will have to be stored and sequestered from the translation machinery until they are 
required.  This mRNA sorting is accomplished by RNA binding proteins that target cis-
elements in the message, binding to the mRNA and preventing translation until a certain 
timepoint in the process has been reached, at which point the message will be released, 




Figure 6.3: Mitotic and Meiotic divisions during spermatogenesis.  Male germ cells 
destined to become spermatids undergo meiotic divisions to reduce ploidy and 
morphological transformations to complete the maturation process.  The morphological 
changes (spermiogenesis) are carried out with a transcriptionally silent nucleus using 
proteins that were transcribed and stored at an earlier stage.  This figure was adapted 
from [38]. 




Translin, a highly conserved mammalian protein enriched in the brain and testis, 
was originally discovered as a protein involved in chromosomal translocations associated 
with lymphoid malignancies [39].  Subsequent research by Hecht and coworkers on the 
spatial and temporal control of protein expression during spermatogenesis in mice 
identified a 26KDa trans element involved in maintaining translational dormancy on sets 
of testis specific mRNAs known as protamines [40].  This trans acting factor was named 
Testis Brain RNA Binding Protein (TB-RBP) and later proved to be the mouse ortholog 
of translin, differing at only 3 of the 228aa residues (99% identity) [40].   
From the primary sequence, it was predicted that translin contained a nuclear 
export signal and a putative leucine zipper motif (Figure 6.4).  Two sets of basic residues, 
amino acids 56-64 and 86-97, were identified as being involved in DNA and RNA 
recognition, and site-directed mutants in the 86-97 region were shown to abolish DNA 
binding activity completely.  It was proposed that the physiological targets of translin are 
conserved sequences in the 3’ UTR of protamine mRNAs designated Y and H elements 
(Figure 6.5) [41].  However, it has subsequently been demonstrated that Y and H 
elements are not requisite for RNA binding by translin, and in fact, translin has been 
shown to bind to several RNA and DNA sequences [42, 43].  Furthermore, since translin 
was subsequently shown to bind to DNA sequences not associated with translocation 
hotspots, its putative role in recombination has been called into question [43].   
Translin has also been identified as a transporter of mRNAs in neurons and male 
germ cells; it therefore comes as no surprise that it requires partner proteins to 
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accomplish this task.  This is especially important in the testis where mRNA transport is 
required to maintain genetic equivalence between X and Y chromosome carrying sperm 
cells.  Translin has been shown to interact with several different proteins including an 
ATPase, a kinesin family member, and a protein component of the cytoskeleton, and 
these interactions highlight its role in intra and intercellular transport of RNA cargoes 




Figure 6.4: The domains of translin.  Nb and Cb represent basic regions known to be 
involved in nucleic acid recognition with their relative positions in the sequence 
designated as being closer to the N-terminus or C-terminus, respectively.  NES and LZ 
represent translin’s nuclear localization signal and leucine zipper, respectively.  C is 
Cys225, the presumed site of intramolecular disulfide bonds between translin monomers 





Figure 6.5: The 3’UTR of the protamine-2 (PRM-2) mRNA.  This 39-mer contains 
sequences designated Y and H elements, which were proposed to be the in vivo targets of 
translin.  This figure was adapted from [42]. 
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Electron Microscopy Structure of Translin 
 
The EM structure of translin showed that it exists as an octameric complex in 
solution with the eight monomers arranged like a pinwheel around a central cavity 
(Figure 6.6).  The EM structure of translin existed as either a single or double octameric 
ring, but not higher order aggregates [47].  Each translin monomer appeared to exist in a 
two domain module in the octamer.  The “tunnel” through the ring is tapered with a 
diameter of 50Å at one end and 30Å at the other.  The entire octameric particle is 115Å 
in diameter.  Addition of a 24 base DNA substrate resulted in the central channel being 
filled with density, implying that DNA substrates are bound at the center of the octamer 
(Figure 6.6) 
It was observed that the DNA makes contact with four of the translin subunits, 
with the two subunits being next to each other in the ring.  The binding of a 39-nt Y and 
H element containing RNA sequence was also investigated by EM with the RNA also 
occupying the central channel of the ring [47].  However, the specifics of the RNA 
recognition compared to the DNA recognition did differ.  First, whereas the DNA 
sequence was recognized through two points of contact occurring between two sets of 
adjacent translin monomers, the RNA was observed to make four points of contact with 
alternating translin monomers.  Additionally, the DNA-translin interaction was only 
observed to take place at the wide end of the translin ring resulting in the DNA density 
only being observed at one end.  In contrast to this result, the RNA ligand was found to 
bind at both the top and bottom of the channel.  In particular, this observation was 
consistent with mutational studies that demonstrated that both basic regions in translin, 
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residues 56-64 and 86-97, are used for interaction with RNA but only the C-terminal 




Figure 6.6: EM structure of the Translin complex.  (Left) Translin (Middle) Translin 
complexed with DNA (Right) Translin complexed with RNA.  Translin exists as an 
octameric disc, ~115 Å in diameter, with the eight subunits centered around a central 
hole.  The binding of an RNA or DNA ligand was observed to fill the central cavity, with 
the DNA ligand making two points of contact and the RNA ligand making four.  These 
images are from [47].     
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Crystal Structures of Mouse and Human Translin 
 
Presently there are two crystal structures of translin from the mouse and human 
isoforms.  The mouse translin (tb-rbp) structure was solved to 2.65Å resolution in the 
orthorhombic P21212 space group with 4 translin monomers in the asymmetric unit.  Each 
translin monomer is 80Å in length and the dimensions of the globular part of the protein 
are 20Å x 35Å x 50Å (Figure 6.7).  The four translin monomers are arranged around a 
pseudo 4-fold axis that can be dimerized to form an octamer in the shape of a prolate 
ellipsoid (Figure 6.8) [48].  The structure is almost exclusively alpha helical with more 
than 70% of the protein’s 228 amino acid residues found in the structure’s 7 alpha helices 
[48].   
The protein core is centered around helix 3, with helices 1 and 2 lying on one side 
and helices 5, 6, and 7, which form the C-terminal region, on the other [48].  The 
structure of the C-terminal portion of the protein was of particular interest since it 
contained a putative leucine zipper domain [40].  It had been demonstrated that point 
mutations of two leucines in this sequence abolished octamer formation and consequently 
nucleic acid binding [49].  However, the crystal structure revealed that the leucine zipper 
is nonfunctional in the traditional sense since many of these residues are involved in 
intramolecular contacts of the three helix bundle formed by helices 4, 5, and 6, not 
intermolecular oligomerization contacts between monomers.  Although the C-terminus of 
translin was shown to not contain a leucine zipper in the traditional sense, the protein was 
observed to assemble in an ordered manner with the C-termini of the 4 monomers in each 
asymmetric unit arranged around a pseudo 4-fold axis.  The C-terminal residues Val156, 
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Val159, Thr160, Leu184, Leu212, and Ile214, along with Gln29, Arg36, and Gln43 of 
the first α-helix make the intermolecular contacts that allow for the C-termini to pack in 
this manner [48]. 
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Figure 6.7: The backbone trace of a translin (mouse) monomer.  Each monomer consists 






Figure 6.8: Crystal structure of mouse translin.  The asymmetric unit of translin contains 
four monomers arranged around a pseudo four-fold axis perpendicular to the plane of the 
page in the left diagram and parallel to the plane of the page in the right diagram.
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Figure 6.9: Higher order assembly of the translin complex.  Performing a two-fold 
crystallographic operation results in an octameric translin particle in the shape of an 
elongated ellipsoid of dimensions 10.5nm x 8.0nm containing a central cavity ~ 20Å 
across.  However, this ellipsoid has no open channel running through it, and without 
some sort of rearrangement of the subunits it would not be capable of binding extended 
oligonucleotides   
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The last 10 residues (219-228) of translin were not observed in the crystal 
structure [48].  This segment of the protein may be in a flexible state because of the 
specific crystallization conditions or it could also be the case that these residues only 
adopt a stable confirmation when the oligomer is bound to an RNA or DNA substrate.  
This part of the protein is of particular interest since it contains Cys225, the candidate 
residue that forms disulfide linkages between monomers, and it should be pointed out that 
dissolved translin crystals migrated as dimers on a non-reducing SDS gel, suggesting that 
although not directly observed, a disulfide linkage is present [48, 49].  However, it should 
be noted that this cysteine is not conserved in other translin homologues, and that the 
reducing environment of the cytoplasm would not favor the formation of disulfide 
linkages [48].  In addition to the C-termini packing around a pseudo 4-fold axis, an 
extensive, crystallographic 2-fold dimer interface was also observed [48].  This dimer 
interface is formed from packing interactions between helix 1, the three helix bundle 
formed by helices 5, 6, and 7, and the random coil between helices 2 and 3.  Additional 
intermonomer interactions are also made between the main chain and side chain atoms of 
Tyr85 and Arg86 [48].   
Execution of the 2-fold symmetry operator on a translin dimer creates a tetrameric 
particle with a concave surface, and the dimer interface buries greater than 1700Å2 of 
surface area per monomer (Figure 1.7) [48].  Executing another 2-fold symmetry operator 
on the 4 monomers of the asymmetric unit, which are arranged around a pseudo 4-fold 
axis, results in the construction of an octameric particle in the shape of a prolate ellipsoid 
of approximate dimensions 10.5nm x 8.0nm containing a central cavity ~ 20Å across 
(Figure 6.9) [48].  Residues 86-90 of each monomer, which are known to be crucial for 
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both DNA and RNA recognition, are positioned at the interior of the particle (Figure 
6.10).  The dimensions of the central cavity are such that it could accommodate a small 
piece of RNA, however, this octameric assembly could not bind an extended 
oligonucleotide since there is no “tunnel” for the oligo to enter and exit from [48].  
Therefore, it was concluded that this assembly of monomers does not represent the 
functional form of translin and may represent an intermediate assembly of the protein 
complex [48].     
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Figure 6.10: DNA/RNA binding residues in translin.  The side chains of amino acids 86-
90 are shown as blue spheres and are compacted on the interior of the ellipsoidal particle.  
Because no “tunnel” exists in this structure, this assembly of the translin octamer could 





Human translin crystallized in the orthorhombic space group C2221 with unit cell 
constants a = 129.424Å, b = 135.272Å, and c = 134.345Å.  This structure is very similar 
to the mouse structure, which is expected since these two sequences share 99% identity.  
The human structure crystallized with four monomers in the asymmetric unit, arranged 
around a pseudo four-fold axis, with each one of the monomers being composed of seven 
α-helices (Figure 6.11).  An octameric complex can be generated by executing a two-fold 
symmetry operator, which results in an octameric particle of dimensions 90Å x 90Å x 
110Å with a central cavity ~15Å across.  Furthermore, as with the mouse structure, 
Cys225, the candidate residue for disulphide bond formation and dimerization of two 
translin monomers, was not visible, and the hypothetical leucine zipper of residues 177-
212 was not observed to be a functional leucine zipper in this crystal structure either.  
However, a comparison of the Cα atoms of the mouse and human structures did reveal 
some difference in the relative positions of the tetrameric assembly, perhaps indicating 
that the assembly of translin multimeric complexes has a degree of flexibility.         
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Figure 6.11: The asymmetric unit of human translin.  The side chains of residues 86-90, 
which are known to be required for DNA binding, are packed on the interior and 
inaccessible to extended oligonucleotides.  Both the human and mouse translin structures 






Translin Associated Factor X (Trax) 
 
Yeast two hybrid experiments identified another candidate partner protein for 
translin named translin associated factor x (trax) [50].  Follow up immunoprecipitation 
experiments verified that translin and trax form a heterocomplex in vivo and also revealed 
that the translin●trax heterocomplex is the predominant cellular species [51].   
Trax is a 33KDa protein that shares ~30% sequence identity with translin; it is not 
capable of binding nucleic acids alone [46, 52].  Trax has a functional nuclear 
localization signal and like translin, has a putative leucine zipper sequence (Figure 6.12) 
[46].  The strong link between these two proteins was reinforced when it was 
demonstrated through mouse knockout experiments that deletion of the translin gene led 
to the absence of trax protein in spite of the fact that trax mRNA levels were normal as 
verified by northern blot [53].  This suggests that translin has a chaperone role for trax 
and that trax most likely only exists in vivo as a member of a heteroprotein complex.   
Characterizing trax has proven difficult primarily due to the fact that the pure 
protein is very unstable and has yet to be successfully expressed recombinantly.  
Biochemical studies have shown that trax possesses a functional nuclear localization 
signal and interacts with proteins other than translin [54, 55].  One of these partner 
proteins is C1D a versatile nuclear protein involved in DNA double stranded break repair 
and VD(J) recombination [55].  Further research is requisite to determine whether DNA 
or possibly both DNA and RNA are targeted by translin and what role trax plays in these 
activities.        
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Figure 6.12: The domains of trax.  NLS and LZ represent the nuclear localization signal 




 Translin and trax play important roles in mRNA trafficking and storage, processes 
crucial for development in neurons and male germ cells.  At the onset of this research 
project, a handful of studies on translin had been published, but a consensus RNA or 
DNA sequence that this protein targets had still yet to be identified.  The exact role of 
trax in these processes also had yet to be determined.  Furthermore, although two crystal 
structures of mouse and human translin existed, neither one of them showed how a 
functional translin complex capable of binding extended oligonucleotides was assembled.  
The goals of this study were to characterize the RNA and DNA binding activities of 
translin and the translin●trax complex, with the intent of clarifying trax’s cellular role 
and translin’s target sequence.  Another goal of this study was to crystallize 
translin●oligonucleotide complexes and/or translin●trax complexes, as high resolution 
structures of these complexes would provide specific details into how DNA and RNA 








Plasmids containing the mouse translin gene cloned into pGEX-4T1, (Amersham 
Biosciences, Piscataway, NJ), and the mouse trax gene cloned into pET28a, (Novagen, 
Madison, WI), were generously provided by the Hecht laboratory (University of 
Pennsylvania Medical Center, Philadelphia, PA).  Ni-NTA His-Bind® resin obtained 
from Novagen (Madison, WI).  Glutathione agarose resin was obtained from sigma.  5’ 
fluorescently labeled oligonucleotides were obtained from IDT DNA (Coralville, IA).  
The pre-packed HiPrep 26/60 Sephacryl S-300 High Resolution and HiLoad 16/60 
Superdex prep grade columns were obtained from GE healthcare (Piscataway, NJ).  The 
pET-DUET-1 and pET-39 expression vectors were obtained from Novagen (Madison, 




Expression and Purification of Recombinant Translin  
 
The pGEX-4T1-translin (M. musculus) vector was transformed into E. Coli strain 
BL21(DE3) under the selection of ampicillin.  Fresh transformants were grown in 
Terrific Broth media (Difco) at 37°C until reaching an optical density of 0.7.  Upon 
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reaching this OD the translin-GST fusion protein was expressed by the addition of IPTG 
to a final concentration of 300μM.  Cells were allowed to grow for another 6 hours post 
induction, and were harvested by centrifugation at 4000g for 10 minutes.  Cells were 
resuspended in lysis buffer (25mM Tris-HCl pH 8, 250mM NaCl) and run through a 
French Pressure cell 3 times at 1000 PSI.  Cell debris was removed by centrifugation at 
30,000g for 1 hour and the crude cell lysate was passed though a column packed with a 
glutathione-agarose matrix (Sigma).  The column was washed with 500 mL of a 25 mM 
Tris-HCl pH 8.0, 150 mM NaCl buffer and a 9 mL slurry resuspension of the matrix and 
wash buffer was transferred to a 50 mL conical tube.  50 units of thrombin (Sigma) and 1 
mL of 10X thrombin cleavage buffer was added to the resuspended matrix and the 
cleavage reaction was incubated at 25 °C for 16 hours before the matrix was repacked in 
a 10 mL disposable column and the free translin was eluted with wash buffer (25 mM 
Tris-HCl pH 8.0, 150 mM NaCl).  Protein containing fractions were pooled together and 
dialyzed against a 10 mM Tris-HCl pH 8.0, 50 mM KCl buffer and concentrated.  The 
recombinant translin was further purified by gel filtration using a HiPrepTM 26/60 
Sephacryl S-300 High Resolution column and an AKTA FPLC system (GE Healthcare, 
Piscataway, NJ).  The protein was loaded onto an S-300 column that had been previously 
equilibrated with a 10mM Tris-HCl pH 8, 50mM KCl buffer and run through the matrix 
at a flow rate of 1mL/min.  Protein containing fractions were pooled together, 
concentrated, and stored at 4 °C. 
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Crystallization of Translin●d(GT)15 Complex 
 
The purified translin protein was concentrated to 15-17mg/mL, as determined by 
OD280 absorption readings and Beer’s Law: 
 




C = the protein concentration (mg/mL) 
A = the absorption at 280nM 
ε = the extinction coefficient of translin; calculated as 0.67 (mg/mL)-1cm-1  
b = the cuvette pathlength, 1cm 
 
Translin●(GT)15 crystals were grown from a mother liquor of 0.1M Sodium 
Acetate pH 5.0, 0.1M MnSO4, 20% polyethylene glycol 1000 (Figure 7.1).  Briefly, the 
d(GT)15 ligand was added to translin and allowed to equilibrate for 5 minutes at 4 °C.  
Crystal drops were set up using the sitting drop method by combining 3 μL of the 
translin●d(GT)15 sample with 3 μL of mother liquor in a VDX crystallization plate 
(Hampton Research, Aliso Viejo, CA), sealed with tape, and allowing the drop to 
equilibrate at 4 °C.    
 116
 
Figure 7.1: Translin●d(GT)15 crystals.  Translin●d(GT15) crystals were grown from a 
mother liquor of 0.1M Sodium Acetate pH 5.0, 0.1M MnSO4, 20% polyethylene glycol 
1000.  
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Cryo-cooling and Diffraction of Translin●d(GT)15 Crystals 
 
The translin●d(GT)15 crystals were removed from the sitting drop using a nylon 
loop, soaked in a 0.1M Sodium Acetate pH 5.0, 0.1M MnSO4, 35% polyethylene glycol 
1000 solution, and flash frozen in liquid nitrogen.  The crystals were then mounted for 
data collection.  The initial diffraction frames revealed that the translin●d(GT)15 complex 
diffracted poorly (~ 10Å).  Furthermore, several attempts at crystal optimization were 
unsuccessful in improving data quality, and as a result, no complete data sets of the 
translin●(GT)15 crystals were collected.       
 
 118
Cloning, Expression, and Purification of Recombinant 
Translin●Trax Complex 
 
A plasmid expressing translin and trax from independent promoters was 
constructed by Jennifer Schleit in our laboratory.  The M. musculus genes for translin and 
trax were amplified by high-fidelity PCR and inserted into the pET-DUET1 expression 
vector.  The M. musculus trax gene was amplified using the forward primer of sequence 
5′-GCGCGGATCCATGAACGGCAAAGAAGGACC-3′ (BamHI restriction site shown 
in bold and underlined) and the reverse primer 5′-
GCCCAAGCTTTTAAGAAATGCTCTCTTCCTGATC-3′ (HindIII recognition site 
shown in bold and underlined).  This 290aa ORF encodes a 6X HisTag fused to the N-
terminus.  The M. musculus translin gene was amplified using the forward primer of 
sequence 5′-GGAATTCCATATGTCTGTGAGCGAGATCTTCGTG-3′ (NdeI 
restriction site shown in bold and underlined) and the reverse primer 5′-
CGCGGTACCCTATTTTTCACCACAAGCCGCTGC-3′ (KpnI restriction site shown 
in bold and underlined).   
The pET-DUET1-translin●trax vector was transformed into E. Coli strain Rosetta 
2 (DE3) under the dual selection of ampicillin and chloramphenicol.  Fresh transformants 
were grown in Terrific Broth media (Difco) at 37°C until reaching an optical density of 
0.7.  Upon reaching this OD600 the translin●trax protein complex was expressed by the 
addition of IPTG to a final concentration of 1mM.  Cells were allowed to grow for 
another 3 hours post induction, and were harvested by centrifugation at 4000g for 10 
minutes.  Cells were resuspended in lysis buffer (25mM Tris-HCl pH 8, 500mM NaCl, 
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10mM imidazole) and run through a French Pressure cell 3 times at 1000 PSI.  Cell 
debris was removed by centrifugation at 30,000g for 1 hour and the crude cell lysate was 
passed though a column packed with Ni-NTA His-Bind® resin.  The column was washed 
with 500 mL of a 25 mM Tris-HCl pH 8, 500mM NaCl, 10 mM imidazole buffer and the 
heterocomplex was eluted with a linear gradient from10 – 250mM imidazole.  Protein 
containing fractions were pooled together and dialyzed against a 10 mM Tris-HCl pH 
8.0, 50 mM KCl buffer and concentrated.  The recombinant translin●trax was further 
purified by gel filtration using a HiPrepTM 26/60 Sephacryl S-300 High Resolution 
column and an AKTA FPLC system (GE Healthcare, Piscataway, NJ).  The protein was 
loaded onto an S-300 column that had been previously equilibrated with a 10mM Tris-
HCl pH 8, 50mM KCl buffer and run through the matrix at a flow rate of 1mL/min.  
Protein containing fractions were pooled together, concentrated, and stored at 4°C.        
 
Gel filtration Analysis of the Translin●Trax Complex   
 
Gel filtration experiments of the recombinant translin●trax complex were carried 
out using a HiPrepTM 26/60 Sephacryl S-300 High Resolution column and an AKTA 
FPLC system (GE Healthcare, Piscataway, NJ).  A 1 mL sample of the translin●trax 
complex was concentrated to 20 mg/mL and passed through the gel filtration system in 
25 mM Tris pH 7.5, 150 mM NaCl buffer at a flow rate of 1mL/min.  The molecular 
weight of the native complex was calculated from the linear regression analysis of a 
calibration curve of Kav vs. log[molecular weight] (where Kav = (protein elution volume – 
column void volume)/(column bed volume – column void volume) that was constructed 
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using the elution profiles of the following protein standards and their respective 
molecular weights: blue dextran (2000 KDa), thyroglobulin (669 KDa), ferritin (440 
KDa), aldolase (158 KDa), conalbumin (75 KDa), and ovalbumin (43 KDa).  The 
majority of the translin●trax complex eluted at a volume that correlates to an apparent 
molecular weight of ~ 340 KDa.       
 
Fluorescence Polarization Assays 
 
Fluorescence polarization (FP) is a convenient and robust technique for measuring 
the association of ligands with macromolecules.  A fluorescent ligand tumbles more 
quickly than one bound to a protein.  When exposed to polarized light the free ligand can 
tumble randomly during the fluorescent life time and the emitted light will depolarize, 
while a ligand bound to a large protein will retain some polarization.  Here, fluorescently 
labeled polynucleotides were titrated with binding proteins (translin or translin•trax); as 
binding increases fluorescence polarization (FP) increases.   
Serial dilutions of stock protein samples were prepared using storage buffer as the 
diluent.  For each 30 μL sample, 3 μL of 10X binding buffer (250 mM Tris-HCl pH 8, 
1M NaCl, 10 mM MgCl2) was combined with a stock fluorescent nucleotide solution and 
a balancing volume of stock protein sample to give a final nucleotide concentration of 5 
nM.  The eight nucleic acid ligands used were designated rGA, rCA, dGA, dCA, rGAG, 
dGAG, PRM-2, and d(PRM-2); their sequences were A(GA)12, A(CA)12, d(A(GA)12), 
d(A(CA)12), A(GAG)8, d(A(GAG)8), 
UCUGAGCCCUGAGCUGCCAAGGAGCCACGAGAUCUGAGU, and 
 121
d(UCUGAGCCCUGAGCUGCCAAGGAGCCACGAGAUCUGAGU), respectively.  
All eight of these ligands had 5’ fluorescein modifications.  These ligands were chosen 
based on a previously published study investigating the nucleic acid binding activity of 
the translin●trax complex purified from brain tissue extracts [42].  The 39nt PRM-2 
sequence was taken from the 3’ UTR of the protamine-2 mRNA and represents an in vivo 
target of translin.  Prior to addition of the nucleotide to the protein sample nucleotide 
solutions were heated to 70 °C and cooled at 25 °C for 3 minutes.  20 μL of each protein-
nucleotide sample was added to a 384 well plate (Thermo Fisher Scientific, Rochester, 
NY), and fluorescence polarization was read using the Perkin Elmer Envision plate 
reader.  Scatter plots of translin concentration and translin●trax concentration vs. 
polarization were constructed using Sigma Plot (Systat Scientific, San Jose, CA) and fit 
to a hyperbola.  
 
Cloning, Expression, and Purification of DsbA●Trax 
 
The M. musculus gene for trax was amplified by high-fidelity PCR and inserted 
into the pET-39 expression vector.  The M. musculus trax gene was amplified using the 
forward primer of sequence 5′- 
ATGGCGATATCGGATCCGTCGCCAAAATCGGATCTGGTTCCGCGTGGAAGTC
CGTTCGAAAAGGGTATGAACGGCAAAGAAGGACCAGGAGGGTTC-3′ (BamHI 
restriction site shown in bold and underlined, thrombin recognition site shown in bold 




TCTCTTCCTGATCAATCATGTCTG-3′ (NotI recognition site shown in bold and 
underlined).  The 873nt trax ORF encodes was inserted downstream of the 627nt ORF of 
DsbA, resulting in a 70KDa fusion protein with a 6X His Tag sequence in the 64aa linker 
region.  Because the DsbA ORF contains the 19aa pelB leader sequence, the fusion 
protein will be exported to the periplasmic space and can be purified by osmotic shock 
protocols.  The pET39-trax vector was transformed into E. Coli strain BL21(DE3) under 
the selection of kanamycin.  Fresh transformants were grown in Terrific Broth media 
(Difco) until reaching an optical density of 0.7.  Upon reaching this OD600 the 
expression of the DsbA●trax fusion protein was induced by the addition of IPTG to a 
final concentration of 1mM.  Cells were allowed to grow for another 3 hours post 
induction, and were harvested by centrifugation at 4000g for 10 minutes.  Cells were 
resuspended in 30mM Tris-HCl pH 8.0, 20% sucrose buffer at a volume of 400mL of 
buffer for each liter of cell culture.  EDTA was added to a final concentration of 1mM 
along with 10mg of hen egg white lysozyme and the resuspension was allowed to mix at 
4°C for 30mins.  Lysozyme was added to breakdown the cell wall, allowing for the 
release of the contents of the periplasmic space into the buffer.  MgCl2 was then added to 
a final concentration of 5mM and the resusupension was centrifuged for 10min at 
10,000g to remove the spheroplasts.  The supernatant was decanted and 10X IMAC 
buffer (250mM Tris pH 8.0, 5M NaCl, 100mM imidazole) was added to the supernatant 
to give final concentrations of 25mM Tris-HCl pH 8.0, 500mM NaCl, 10mM imidazole.  
The supernatant was then loaded onto a column packed with Ni-NTA His-Bind® resin 
that had been pre-equilibrated with 1X IMAC buffer.  The column was washed with 500 
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mL of 1X IMAC buffer and the fusion protein was eluted with a linear gradient from10 – 
250mM imidazole.  Protein containing fractions were pooled together and dialyzed 
against a 10 mM Tris-HCl pH 8.0, 50 mM KCl buffer, concentrated, and stored.          
 
Western blot Analysis of DsbA●Trax        
 
The DsbA●trax fusion protein was run on a 12% SDS page gel and the protein 
sample was transferred to a PVDF membrane (Millipore) at 100mA for 20 minutes using 
a blotting apparatus (Bio-Rad).  The membrane was then incubated with blocking buffer 
(10mM Hepes pH 7.6, 150mM NaCl buffer containing 5% milk) for 2 hours at room 
temperature.  The anti-trax antibody (rabbit) was diluted 1:1000 in blocking buffer and 
incubated with the PVDF membrane for 1 hour at room temperature.  The membrane was 
then washed three separate times with blocking buffer for 5 minute incubations.  The 
Horseradish Peroxidase conjugated secondary antibody (goat anti-rabbit) was diluted 
1:6000 in blocking buffer and incubated with the PVDF membrane for 1 hour at room 
temperature.  The membrane was then washed three separate times with blocking buffer 
for 5 minute incubations then an additional three times with 10mM Hepes pH 7.6, 
150mM NaCl.  The presence of the DsbA●trax fusion protein was detected using 
SuperSignal West Pico Chemiluminescent Substrate.    
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Chapter 8: Results 
 
Expression, Purification, and Gel Filtration Analysis of 
Translin●Trax Complex  
 
The recombinant translin●trax complex was successfully expressed in E. coli 
using a dual expression vector that contained two open reading frames (ORFs) with two 
separate T7 promoters.  The recombinant complex was purified to homogeneity by 
Immobilized Metal Affinity Chromatography (IMAC) using a linear imidazole gradient 
followed by size exclusion chromatography.  Because only the trax ORF encodes an N-
terminal 6x-His tag, translin can only be purified from the Ni resin through its interaction 
with trax.  When analyzed on a 12% SDS PAGE gel, the trax and translin bands appear to 
be present in a roughly 1:1 ratio (Figure 8.1).  
The apparent molecular weight of the translin●trax complex was determined by 
gel filtration analysis on a sephacryl S-300 column, against high molecular weight, 
globular protein standards.  The data (Figure 8.2) suggest a molecular weight for the 
complex of ~340 KDa, while that for pure translin was ~280 kDa.   
These data would seem consistent with the notion that the complex is a 
heterodecamer of the form translin5•trax5 and that translin exists as a decamer.  However, 
it should be noted that if the heteromeric complex, and translin, form cyclic disks, then 
the apparent volume of each complex in solution would be larger than a sphere of the 
same mass, and would run aberrantly heavy.  Therefore, because translin has been 
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observed as an octameric complex in electron microscopy and ultracentrifuge studies, it 
seems plausible to conclude that the true composition of the complex is most likely a 




Figure 8.1: A 12% SDS gel of translin and translin●trax.  Lane 1: molecular weight 
standards; Lane 2:  recombinant mouse translin (26 KDa); Lane 3:  recombinant mouse 
translin●trax complex (translin 26 KDa, trax 33 KDa).    
.   
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Figure 8.2: Gel filtration of the translin●trax complex.  The elution profile of the 
recombinant translin●trax complex eluting from a sephacryl S-300 column.  The elution 
volumes of thyroglobulin (669 KDa), ferritin (440 KDa), aldolase (158 KDa), 
conalbumin (75 KDa), and ovalbumin (43 KDa) are shown as dashed lines. 
   
 128
RNA and DNA Binding by Translin and Translin●Trax 
  
To quantitatively investigate the binding of nucleic acids to translin, eight RNA 
and DNA ligands with 5’ fluorescein modifications were used: RNA ligands were PRM-
2, rGA, rGAG, and rCA, and DNA ligands d(PRM-2), dGA, dGAG and  dCA,  (as 
defined in Materials and Methods).  The binding of polynucleotides to recombinant 
translin as observed through the change in fluorescence polarization (FP) is shown in 
Figure 8.3 and the binding constants are summarized in Table 8.1.  For these binding 
curves, the concentration of translin is defined as an octameric binding complex.   
Translin was observed to bind the YH element containing PRM-2 mRNA, with a 
Kd of 200 nM. It bound the synthetic rGA with an even higher affinity, Kd = 20 nM.  The 
rCA and rGAG polymers bound more weakly, with a Kd of 0.9 and 0.5 μM, respectively.  
In general, translin bound deoxyribonucleotides more poorly than ribonucleotides.   For 
example, the dPRM-2 and dGA oligonucleotides each bound about 50 times worse than 
the corresponding RNA sequence.  The oligonucleotide binding data for the translin●trax 
heterocomplex is shown in Figure 8.4.  For these binding curves the concentrations 
shown represent the hetero-octamer, translin4•trax4, as the binding unit.  In general, the 
translin●trax complex bound these oligonucleotides weaker than translin alone.  Also, in 
contrast to translin the heterocomplex bound tighter to DNA sequences than RNA 
sequences, the opposite of the pattern displayed by translin.  The physiological RNA 
substrate, the YH element containing PRM-2, has a Kd of 40 μM, about 100 times weaker 
than the binding of the same ligand to translin alone.  However, consistent with the 
general trend, the translin●trax complex does bind d(PRM-2)10-fold tighter than it binds 
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the equivalent RNA sequence, and 5-fold tighter than translin binds this DNA ligand.  
The synthetic ribonucleotides bind the complex with Kd values between about 30 and 100 
μM.  In marked contrast, the G-rich DNA polymers bind the complex avidly; dGA and 
dGAG have Kds of 100 and 175 nM, respectively.   The binding experiments suggested 
that, in general, translin and translin•trax prefer to bind to GA rich sequences, translin 
binds stronger to RNA, and the translin•trax complex binds stronger to DNA. 
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Table 8.1: Dissociation Constants for Translin8 and Translin4●Trax4 Binding to 
RNA and DNA Ligands 


































   
 
 
Figure 8.3: RNA and DNA binding by the translin complex.  A plot of translin binding 
to rGA, rCA, dGA, dCA, rGAG, dGAG and PRM-2.  GA sequences are represented as 
circles, CA sequences are represented as squares, GAG sequences are represented as 
inverted triangles, and PRM-2 is represented as triangles.  RNA sequences are shown as 
open symbols and DNA sequences are shown as filled symbols.  Inset: a plot of translin 
binding to d(PRM-2).  Both plots were constructed using the translin octamer as the 
binding protein.     
 132
 
Figure 8.4: RNA and DNA binding by the translin●trax complex.  A plot of 
translin●trax binding to rGA, rCA, dGA, dCA, rGAG, dGAG, PRM-2 and d(PRM-2).  
GA sequences are represented as circles, CA sequences are represented as squares, GAG 
sequences are represented as inverted triangles, and PRM-2 is represented as triangles.  
RNA sequences are shown as open symbols and DNA sequences are shown as filled 
symbols.  This plot was constructed using the translin●trax hetero-octamer as the binding 
protein.    
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Analysis of Translin Binding PRM-2 Derivative Sequences 
 
Because the initial binding studies showed that translin has affinity for GA rich 
RNA sequences, the role that GAG trimers have in the recognition of PRM-2 was 
explored.  Two separate GAG trimers in the PRM-2 sequence were mutated to CAC, and 
a double mutant in which both trimers were altered was also used.  These sequences, 
derived from PRM-2, were designated PRM-2 variants 1, 2 and 3 and are shown in Table 
8.2.  The bases that were mutated in the variant sequences are underlined.  We also made 
a truncation variant in which the last 9 bases were removed from the 3’ end of the 
oligonucleotide (labeled PRM-2(1-30)). Table 8.2 shows the Kd values for the binding of 
these variant sequences to translin and the binding data is shown in Figure 8.5 and 8.6.  
Translin was observed to bind to PRM-2 Variant 1 with a Kd of 1 μM, a slight reduction 
in affinity from the wt PRM-2 sequence (Kd = 0.2 μM ).  It bound the other two mutant 
ligands, variants 2 and 3, and the truncation variant, with no significant decrease in 
affinity (Kd of 0.2, 0.3, and 0.2 μM, respectively).   
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Table 8.2: Dissociation Constants for Translin8 Binding to PRM-2 and Variant 
PRM-2 Sequences 





























Figure 8.5: A plot of translin binding to PRM-2 and variant sequences.  PRM-2 is 




Figure 8.6: A plot of translin binding to PRM-2 and PRM-2(1-30).  PRM-2 is represented 
as triangles and PRM-2(1-30) is represented as circles.   
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Expression and Purification of Recombinant DsbA●Trax 
 
The DsbA●trax recombinant fusion protein was successfully expressed and 
purified from the periplasmic fraction (Figure 8.7).  The DsbA●trax fusion protein was 
soluble to at least a concentration of 5mg/mL in 10mM Tris-HCl pH 8.0, 50mM KCl 
buffer.  An attempt to isolate the recombinant trax protein by removal of the DsbA tag by 
thrombin cleavage resulted in the precipitation of over 90% of the trax protein.  
Subsequent attempts to isolate the recombinant trax protein by varying the salt 
concentration, pH, and temperature were also unsuccessful and resulted in precipitation 
of the trax protein.  Several more thrombin digests of the fusion protein were attempted 








Figure 8.7: (Left) A 12% SDS gel of purified recombinant DsbA●trax.  Lane 1: 
Molecular weight marker.  Lanes 2-4: Periplasmic fraction.  Lanes 6-8, 11,12: Purified 
recombinant DsbA●trax (70KDa).  Lanes 9 and 10: BSA (69KDa).  Lane 13: Fraction 
taken from spheroplasts lysate.  (Right) An anti-trax western blot of the purified 









Chapter 9: Discussion  
 
Translin and trax play roles in very important cellular processes, such as DNA 
recombination and the spatial and temporal expression of mRNA, yet the exact 
biochemical details of their roles remain elusive.  A comparative study of the nucleic acid 
binding activities of translin and the translin●trax complex was requisite for defining 
what roles translin, trax, and the translin●trax complex have in recombination, RNA 
trafficking, and the post-transcriptional regulation of gene expression.  It can be 
concluded from these experiments that translin alone prefers to bind GA-rich RNA 
sequences, while the translin●trax complex shifts the binding affinity to GA-rich DNA 
sequences as shown in Table 8.1.  It was observed that translin binds poly-GA with sub-
micromolar affinity, while the translin•trax complex binds poly-dGA with sub-
micromolar affinity.  Conversely, translin binds the corresponding dGA nearly 1000 
times more poorly, while the complex binds the ribonucleotide GA about 25 times more 
poorly.  When the ligand is the GA-rich element from the PRM-2 message, or its 
deoxyribonucleotide variant, we see the same pattern between translin and the complex, 
albeit with less dramatic differences.  This pattern of RNA and DNA preference between 
the two protein complexes is consistent with more qualitative work by others; Hecht and 
coworkers used gel shift assays to show that trax decreases translin’s affinity for a 
specific RNA sequence but increases it’s affinity for specific a DNA sequence [52].   
Trax being able to switch translin’s binding preference between DNA and RNA 
may be important in understanding the physiological role of these two proteins.  Perhaps 
the significance of these observations is most clearly seen in the binding of the natural 
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protamine mRNA sequence, PRM-2; this sequence has been identified as crucial to the 
recognition of mRNA functioning in sperm development (Kwon and Hecht 1991).  We 
see that the mRNA motif binds at least 100 times more tightly to translin than to the 
translin•trax complex.  To reiterate, it is known that trax has a nuclear localization signal 
(NLS) [50], while translin has a nuclear export signal (NES) [52].  At the simplest level 
one might imagine the translin•trax complex being taken into the nucleus using the trax 
NLS. The complex would favor DNA binding in the nucleus.  However, once translin is 
released from trax it favors RNA binding, and can recognize certain mRNAs, like PRM2, 
and carry them into the cytoplasm using its NES. 
Due to a lack of detailed structural data, the specifics of the 
translin●oligonucleotide and translin●trax●oligonucleotide interactions are not known.  It 
appears that the biologically relevant form of translin is a cyclic octamer which binds 
both RNA and DNA in the center [47].  The gel filtration data of the complex suggests it 
is also an octamer, but the organization of the different subunits is ambiguous.  
Therefore, we do not know if translin has active site binding pockets that may 
preferentially bind guanine compared to other bases.  It is clear from these results that G-
rich nucleotides are bound strongly by translin, but it is not known whether or not this is a 
result of these protein complexes assembling in such a way as to create guanine binding 
pockets or the result of a tertiary conformation of the G-rich nucleotide being 
preferentially recognized.  Additionally, how the interaction of trax, which appears to 
lack nucleic acid binding capacities, switches translin’s affinity from RNA to DNA also 
is not clear.  DNA bases have subtly different chemical properties from their RNA 
counterparts, not the least of which is the lack of a 2’ hydroxyl, but they also have more 
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prominent structural differences.  Presumable the switch in specificity arises from a 
structural change that shifts from reading A form RNA to B form DNA.  Furthermore, it 
was observed that translin’s physiological target, PRM-2, contained four GAG 
sequences.  Assuming that translin assembles and exists as an octameric disk, one would 
expect the octamer to have eight binding sites, and a polymer with the correct eight fold 
repeat might bind very tightly.  However, as shown in Table 8.1, translin bound (GAG)8 
more weakly than the PRM-2 sequence, and binds only 1/20th as well as (GA)12.  This 
suggests that the binding of RNA to translin is more complex than simply reading base 
sequences by eight symmetrically related active sites.  As previously stated, we do not 
know the structure of the translin•trax complex, but the simplest model would be a 
hetero-octameric disc with four translin•trax pairs, and four translin active sites at 90° 
intervals.  It is interesting to note that both the d(GA)12 and d(GAG)8 oligonucleotides 
have four evenly spaced GAG sequences and they both bind to the complex with sub-
micromolar affinities.  This result may be indicative of the complex, in contrast to 
translin, reading the bases directly. 
To further investigate the roles of GAG trimers in ligand recognition by translin, 
two GAG trimers at positions 11-13 and 29-31 were separately and jointly mutated to 
CAC, and their binding affinities measured (Table 8.2).  The mutations in the first PRM-
2 variant sequence yielded a slight, but reproducible, reduction in translin’s affinity for 
PRM-2 (Kd 1 μM and Kd 0.2 μM respectively).  However, the mutations of the other two 
variant sequences did not perturb binding.  This is somewhat difficult to rationalize since 
the double mutant includes the 11-13 mutation which does perturb binding.  One possible 
explanation for this effect can be seen by examining Figure 4.1, which shows the 
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predicted secondary structure of the PRM-2 variants [56].  The PRM-2 sequence and the 
tighter binding variants all exhibit a stem loop structure with two unpaired A bases in the 
stem.  The weaker binding variant 1 is predicted to have a distinct secondary structure 
that lacks this feature.  The experimental data combined with this secondary structure 
prediction suggests that translin may recognize secondary structural element in the RNA 
that presents the bases in the correct orientation for optimum protein-RNA interaction.  
To extend this study slightly, we measured the binding affinity of translin to a truncated 
30-mer PRM-2 (PRM-2(1-30)) ligand; it contains only the putative stem loop structure of 
the bases 1 – 30, and lacks the last nine 3’ bases (Figure 9.1).  Translin bound to this 




Figure 9.1: Secondary structures of RNA ligands derived from PRM-2.  The predicted 
secondary structures for PRM-2 and the four PRM-2 variant sequences as determined 
using the Vienna RNA web server [56].  
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These results are consistent with the hypothesis that the protein’s endogenous 
target may be a secondary structure in the 3’ UTR of the mRNA.  Extensive structural 
research shows that DNA sequences containing G-tracts as short as G2 can fold into 
distinct secondary structures [57].  This fact adds to the difficulties of interpreting this 
binding data in a completely straightforward and consistent fashion.  It may be, for 
example, that in its biological role, translin binds a range of Y and H element containing 
RNAs with a Kd in the low micromolar range (Table 8.1).   Each may form a secondary 
structure that binds in the central cavity of the octameric disk and makes some specific 
contacts. The unusually tight binding of rGA may arise adventitiously because it 
assumes, by chance, the best fold to maximize binding interactions. 
In discussing the roles for translin and the complex with trax it is important to 
note that trax has also been shown to interact with the versatile nuclear protein C1D [55].  
C1D interacts with trax as part of a cellular DNA repair response.  Furthermore, the 
trax●C1D and translin●trax interactions are mutually exclusive, and consequentially, the 
interaction between trax and C1D may regulate the formation of translin●trax complexes.  
For example, the trax●C1D interaction may prevent translin or translin●trax from 
participating in recombination events before DNA repair mechanisms are complete [55].  
Trax’s ability to change protein partners between translin and C1D could act in vivo to 
switch translin from a DNA-binding protein to an RNA-binding protein.  This is 
generally consistent with, the model proposed by Hecht and coworkers that trax can 
regulate translin’s subcellular locale as shown in Figure 9.2 [54].  It has previously been 
demonstrated that both trax and translin co-localize to the nucleus in meiotic pachytene 
spermatocytes and co-localize to the cytoplasm in post meiotic spermatids [54].  Once in 
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the nucleus, this complex can interact with DNA, presumably functioning in DNA 
crossing over which occurs at this stage.  Thereafter, trax dissociates, exchanging translin 
for C1D, and freeing translin to interact with mRNAs marked for export from the nucleus 
via translin’s NES [54, 55].  Once translin has re-entered the cytoplasm, it can remain 
bound to the mRNA until a cellular signal for release and subsequent translation of the 
message has been received [54].  This transport has been observed in nerve cells and in 
developing spermatids [41, 44-46, 58-63].  The ability to act as a shuttling protein that 
transitorily localizes to the nucleus is a hallmark of the RNA-binding proteins that traffic 
mRNAs in neuronal cells [36].  This notion is strengthened by the key observation that 
once localized to the nucleus translin binds an mRNA cargo, which is also characteristic 




Figure 9.2: Nucleocytoplasmic shuttling by the translin●trax complex.  This model was 
proposed by Hecht and coworkers [54].  In pachytene spermatocytes, when exchange of 
genetic information can occur, the trax/translin ratio is elevated allowing for trax to 
associate with translin, and most likely other proteins like Ter ATPase.  Once this 
complex has formed it can gain entry into the nucleus using trax’s NLS.  Once in the 
nucleus translin alone, or complexed with trax or other partner proteins like C1D can 
interact with DNA or RNA.  In round and elongated spermatids, translin containing 
complexes are predominantly found in the cytoplasm and contain the partner proteins Ter 
ATPase and KIF17.  These complexes have been observed to shuttle mRNA through 




Chapter 10: Conclusion 
 
In this study, a comparative oligonucleotide binding experiments between translin 
and translin●trax were carried out.  From the data collected, it can be concluded that 
translin functions primarily as an RNA binding protein that favors G-rich sequences and 
seems to target a secondary structure in the RNA as opposed to a liner sequence of bases.  
To the contrary, translin●trax binds almost exclusively to G-rich DNA sequences.  It can 
be concluded that trax’s interaction with translin acts to decrease translin’s affinity for 
RNA and decrease its affinity for DNA; in other words converting translin from an RNA 
binding protein to a DNA binding protein.  This property of trax may indicate that it 
functions in the cell as a regulatory factor for translin during mRNA trafficking since trax 
can change translin’s subcellular locale in addition to its oligonucleotide binding 
activities.     
 148
Chapter 11: Future Work 
 
Future work should focus on alternative approaches to structural studies of 
translin and trax.  Specifically, since trax could not be successfully cleaved from DsbA, 
further attempts to crystallize this fusion protein would be worthwhile since structural 
data on trax in any form may provide new information into how it functions.  
Additionally, high throughput oligonucleotide experiments using both translin and 
translin●trax as targets could prove useful to further clarify what these protein complexes 
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